Podcasts about Maturin

Prends pas Ã§a pour du cash

Play Episode Listen Later Aug 26, 2024 41:01

maturin

Maturin livre les aliments du fermier jusqu'à votre porte!

Play Episode Listen Later Jul 4, 2024 13:17

Entrevue avec Jonathan Bélanger, président et co-fondateur de MaturinPour de l'information concernant l'utilisation de vos données personnelles - https://omnystudio.com/policies/listener/fr

votre jusqu porte entrevue aliments livre les fermier jonathan b maturin

June 27th 2024 - Hour Two Shelly Maturin and Elizabeth Murrill interview

netflix social media monkeys roundtable engage misery maturin

Play Episode Listen Later Jun 27, 2024 42:18

maturin

Round Table #149

Dark Tower Palaver

Play Episode Listen Later Apr 7, 2024 113:07

In the latest Round Table Tadd and Peter talk about various news including Maturin now being a real turtle, Life of Chuck, The Monkey, Carrie (and King's career) hitting its 50th Anniversary, a Netflix show that seems like a modern take on Misery but is a true story, and talk about the March Insanity that was and looking ahead at 2025! Engage with the show by Email or Social Media! Check the website at DarkTowerPalaver.com or Patreon at patreon.com/darktowerpalaver

December 20th 2023 - Hour One Shelly Maturin interview

Medianálisis contra la desinformación

Play Episode Listen Later Dec 20, 2023 45:07

hour one maturin

Sindicato de Empleados de Salud (Monagas) denuncia mal estado de morgue en el Hospital Universitario de Maturin

Play Episode Listen Later Dec 1, 2023 1:31

Te presentamos una nueva entrega del Micro Informativo "Medianálisis Informa"

hospitals estado salud informa denuncia sindicato median empleados morgue hospital universitario monagas maturin

From PharmD to Pharmacogenomics Test Developer: Dr. Thierry Dervieux's Story of Revolutionizing Healthcare Through Precision Medicine for Immune Modulated Inflammatory Diseases | PGx For Pharmacists

PGX for Pharmacists

Play Episode Listen Later Nov 20, 2023 28:46

Becky Winslow, BS, PharmD Host and Pharmacogenomics Medical Science Liaison; Behnaz Sarrami, MS, PharmD, Host and Pharmacogenomics Medical Science Liaison; Thierry Dervieux, PharmD, PhD, Chief Scientific Officer at Prometheus Laboratories Disclaimer: Behnaz Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of Castle Biosciences, Inc. Becky Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of any other entity. Transcription: 1 00:00:06,190 --> 00:00:19,620 You're listening to the Pharmacy podcast Network in a world where one size fits all medications dominate the pharmaceutical industry. 2 00:00:20,079 --> 00:00:24,750 Precision medicine brings a ray of hope for those seeking customized health care. 3 00:00:25,350 --> 00:00:32,830 Pharmacists have a unique opportunity to help people in need of specialized testing to ensure medications work as intended. 4 00:00:33,540 --> 00:00:44,680 Welcome to PGX for pharmacists where we unravel the wonders of precision medicine and its potential to revolutionize the way we approach pharmacy care. 5 00:00:45,169 --> 00:00:52,790 Get ready to uncover the secrets behind pharmacogenomics and how it's transforming lives one genome at a time. 6 00:00:52,799 --> 00:00:53,189 Hello, 7 00:00:53,200 --> 00:00:53,950 everyone. 8 00:00:54,159 --> 00:00:55,080 I'm your host, 9 00:00:55,090 --> 00:00:56,389 Doctor Becky Winslow. 10 00:00:56,409 --> 00:01:09,860 And you're listening to the PGX for Pharmacist podcast that we magazine recognized in 2021 as the ninth most listened to genetics podcasts in the world on the PGX for Pharmacist podcast. 11 00:01:09,870 --> 00:01:16,690 We explore all things pharmacogenomics related and our mission is to educate and advocate for PGX. 12 00:01:16,769 --> 00:01:23,849 We accomplish this mission through exclusive interviews with highly qualified and well experienced pharmacogenomics. 13 00:01:23,860 --> 00:01:29,720 Industry leaders such as today's special guest and my name is Baas Sami, 14 00:01:29,730 --> 00:01:32,739 the co-host of PGX for Pharms podcast, 15 00:01:32,750 --> 00:01:33,860 Pharmacogenomics, 16 00:01:33,870 --> 00:01:36,819 medical science liaison and a mentor to pharmacist. 17 00:01:36,889 --> 00:01:40,239 Connect with us on linkedin and let's get a conversation going. 18 00:01:40,269 --> 00:01:46,720 We want to hear from you and how you're impacting pharmacogenomic stakeholders and what you have learned throughout your journey. 19 00:01:48,510 --> 00:01:49,010 Ok. 20 00:01:49,019 --> 00:01:50,819 So without any further ado, 21 00:01:50,839 --> 00:01:54,769 I'm extremely pleased to introduce to our audience. 22 00:01:54,919 --> 00:01:56,059 Doctor Theory Devo, 23 00:01:57,239 --> 00:02:01,129 the Chief Scientific Officer at Prometheus Laboratories, 24 00:02:01,139 --> 00:02:08,139 and Perme Prometheus Laboratories is a reference clinical laboratory that's focused on the diagnosis, 25 00:02:08,149 --> 00:02:13,330 prognosis and monitoring of immune mediated inflammatory diseases. 26 00:02:13,970 --> 00:02:14,229 So, 27 00:02:14,240 --> 00:02:14,649 thank you, 28 00:02:14,660 --> 00:02:17,759 Doctor De for joining us on the podcast. 29 00:02:17,770 --> 00:02:18,589 Today. 30 00:02:18,600 --> 00:02:23,190 I'm excited to share your and Prometheus's story with our audience. 31 00:02:23,649 --> 00:02:25,630 Um in particular, 32 00:02:25,639 --> 00:02:45,369 I'm excited about you sharing your career journey as a farm D phd and Chief scientific officer and designer of the Predictor PK AD A which is a precision guided dosing test for the optimization of Humira Remicade and their bio cylinders. 33 00:02:46,119 --> 00:02:46,449 So, 34 00:02:46,460 --> 00:03:04,220 one of Bana's and my main goals for this episode of the PGX for Pharmacist podcast is to expand our audience's notion of what a PGX test looks like and to inspire them to think bigger than the traditional box PGX test. 35 00:03:04,229 --> 00:03:08,020 Most of them or most of you are uh familiar with. 36 00:03:09,020 --> 00:03:09,429 So, 37 00:03:09,440 --> 00:03:22,179 Doctor D uh I'd like to start the podcast by having our guests um introduce themselves and elaborate on how you are a pharmacogenomics expert. 38 00:03:23,619 --> 00:03:23,800 Yeah, 39 00:03:23,809 --> 00:03:24,250 thank you, 40 00:03:24,259 --> 00:03:25,759 Becky for having me. 41 00:03:25,770 --> 00:03:26,850 Uh uh Yes. 42 00:03:26,860 --> 00:03:27,289 So I am a, 43 00:03:27,300 --> 00:03:30,820 I am a pharmacist uh with uh a family who is a, 44 00:03:30,830 --> 00:03:33,039 a doctorate in pharmacokinetics. 45 00:03:33,539 --> 00:03:44,520 Uh I completed my studies in France and I came as a postdoc uh fellow uh to work in the United States about 20 years ago to work on the pharmacogenomic of anti cancer agents, 46 00:03:44,929 --> 00:03:49,160 uh primarily uh six Maturin as well as methotrexate. 47 00:03:49,169 --> 00:03:50,550 After my post doc, 48 00:03:50,770 --> 00:03:52,960 uh I moved uh in industry for promet. 49 00:03:53,490 --> 00:04:01,429 So I have a large experience in uh uh the implementation of pharmacogenetics testing in immune mediated inflammatory disease. 50 00:04:01,509 --> 00:04:12,550 Our lab Rome was the first uh clinical laboratory in the United States to offer the fin uh metyl transfer genotyping as well as the thin metabolites. 51 00:04:12,559 --> 00:04:13,029 So, 52 00:04:13,050 --> 00:04:21,989 uh uh of uh of 70 publications in the field and uh I'm very uh very excited to have uh to be on the postcard with you uh uh today. 53 00:04:23,660 --> 00:04:24,220 All right. 54 00:04:24,230 --> 00:04:27,359 So thank you for qualifying yourself as an expert. 55 00:04:27,369 --> 00:04:27,619 So, 56 00:04:27,630 --> 00:04:32,839 let's jump right in and delve into your current PGX work. 57 00:04:32,850 --> 00:04:33,279 So, 58 00:04:33,489 --> 00:04:36,540 if you'll tell us um a little about Prometheus, 59 00:04:36,549 --> 00:04:38,000 specifically, 60 00:04:38,010 --> 00:04:40,350 what is Prometheus's mission? 61 00:04:40,359 --> 00:04:43,799 And how are you guys going about accomplishing your mission? 62 00:04:44,760 --> 00:04:44,980 Yeah, 63 00:04:44,989 --> 00:04:45,700 sure. 64 00:04:45,709 --> 00:04:47,459 Uh So Promet is a, 65 00:04:47,470 --> 00:04:52,790 is a reference uh clinical laboratory based in Southern California in San Diego. 66 00:04:53,230 --> 00:04:56,809 Uh The company has been there for uh over 25 years. 67 00:04:56,820 --> 00:05:03,950 We are uh specialize in the differential diagnosis of autoimmune G I disease uh disorders, 68 00:05:04,059 --> 00:05:06,019 uh gastrointestinal disorder, 69 00:05:06,230 --> 00:05:08,619 uh and inflammatory bowel disease. 70 00:05:08,980 --> 00:05:10,299 And over the years, 71 00:05:10,309 --> 00:05:16,600 we have developed a portfolio of a differentiated solution to facilitate the diagnosis, 72 00:05:16,609 --> 00:05:17,470 the prognosis, 73 00:05:17,480 --> 00:05:18,429 the monitoring, 74 00:05:18,660 --> 00:05:21,910 as well as therapy selection with pharmacogenetics testing, 75 00:05:21,920 --> 00:05:24,730 which we are offering to our clinical laboratory. 76 00:05:24,829 --> 00:05:26,350 And most importantly, 77 00:05:26,410 --> 00:05:27,299 uh recently, 78 00:05:27,309 --> 00:05:35,660 we are uh uh developing some uh uh testing solution with the credit topic care test to optimize treatment to uh biologics. 79 00:05:36,470 --> 00:05:37,130 Ok. 80 00:05:37,140 --> 00:05:37,329 Well, 81 00:05:37,339 --> 00:05:37,450 that, 82 00:05:37,459 --> 00:05:38,049 that's great. 83 00:05:38,059 --> 00:05:46,100 Can you also tell us uh about the Prois Library of Precision Medicine Tests for inflammatory bowel disease for patients? 84 00:05:46,109 --> 00:05:49,230 how they benefit medication therapy management. 85 00:05:49,239 --> 00:05:56,429 Stakeholders across the IB DS patients journey from diagnosis to treatment to disease, 86 00:05:56,440 --> 00:06:02,049 monitoring through remission and how they differ from other lab tests for IBD and his treatments. 87 00:06:02,709 --> 00:06:03,209 Yes. 88 00:06:03,220 --> 00:06:03,369 So, 89 00:06:03,380 --> 00:06:04,399 so we uh our, 90 00:06:04,410 --> 00:06:10,100 our clinical laboratory offers some uh highly specialized test to facilitate the, 91 00:06:10,109 --> 00:06:16,779 the diagnostic of uh to facilitate the differential diagnosis of uh uh inflammatory bowel disease. 92 00:06:16,790 --> 00:06:22,359 So we are following uh testing solution with uh serological testing, 93 00:06:22,529 --> 00:06:23,799 for example, 94 00:06:23,809 --> 00:06:38,410 uh uh piana as as as well as uh macro microbial uh uh antibodies that are present uh uh in Crohn's disease as well as uh over uh auto uh auto antibodies that are present in er colitis. 95 00:06:39,339 --> 00:06:43,684 These are conditions that are uh uh somewhat difficult to treat. 96 00:06:43,704 --> 00:06:49,994 Uh And uh we are uh uh offering those tests to uh help uh gastroenterologist. 97 00:06:50,015 --> 00:06:51,114 Uh uh first of all, 98 00:06:51,125 --> 00:07:03,434 to establish a differential diagnosis of IBD as compared to other uh condition typically uh uh irritable bowel syndrome as well as over gastrointestinal disorder. 99 00:07:03,445 --> 00:07:05,635 When the diagnostic is established, 100 00:07:05,910 --> 00:07:31,839 uh we offer uh testing to uh establish a prognosis where we're gonna in inform the clinician that the patient has a more aggressive uh disease that will require more aggressive treatment where uh we can uh provide the testing solution to initiate uh uh the most appropriate therapy for uh for the patient uh with uh a testing where we are uh basically uh you know, 101 00:07:31,850 --> 00:07:36,559 establish de determining some genotyping with the fit transferal genotyping. 102 00:07:36,570 --> 00:07:37,279 For example, 103 00:07:37,290 --> 00:07:40,250 where we can uh indicate that the patient is, 104 00:07:40,260 --> 00:07:45,079 is likely uh to present with a side effect to those medication. 105 00:07:45,399 --> 00:07:46,170 And once you know, 106 00:07:46,179 --> 00:07:47,799 the the treatment is initiative, 107 00:07:47,809 --> 00:08:16,089 we have a portfolio of solution uh to facilitate the monitoring of the disease of the inflammatory bowel disease as well as the dosing optimization with uh uh the answer test which uh measure blood level uh for uh uh monoclonal antibodies that are indicated in the treatment of IB start with starting with Infliximab Adalimumab as well as uh Tein and vidal. 108 00:08:16,980 --> 00:08:24,040 So we have a comprehensive portfolio to uh to surround the clinician with uh a variety of testing solution. 109 00:08:24,049 --> 00:08:30,250 With our goal being to improve the uh the outcome uh of patients with uh with diabetes. 110 00:08:30,260 --> 00:08:34,520 And I think that the pharmacist has a very important role to play from that perspective. 111 00:08:35,179 --> 00:08:36,039 So theory, 112 00:08:36,049 --> 00:08:40,239 could you elaborate for us more on the predictor test? 113 00:08:40,249 --> 00:08:42,758 Um especially since you designed that test, 114 00:08:42,768 --> 00:08:44,218 we'd really like to know, 115 00:08:44,489 --> 00:08:45,039 um you know, 116 00:08:45,049 --> 00:08:49,638 what did that take and what role does it play in your suite of testing? 117 00:08:51,049 --> 00:08:51,270 Yeah. 118 00:08:51,280 --> 00:08:51,890 Sure. 119 00:08:51,900 --> 00:08:52,510 So the, 120 00:08:52,520 --> 00:08:52,570 the, 121 00:08:52,580 --> 00:08:52,989 the, 122 00:08:53,000 --> 00:08:53,229 the, 123 00:08:53,239 --> 00:08:59,960 the predictor test is uh uh is uh is utilized when the patient is receiving treatment. 124 00:09:00,280 --> 00:09:18,190 It's been speci specifically designed to optimize uh biological uh uh disease modifiers such as Infliximab adalimumab that are co therapies in the treatment of inflammatory bowel disease as well as other immune uh mediated inflammatory. 125 00:09:18,200 --> 00:09:21,549 This is what the test does is to you connect the blood specimen, 126 00:09:22,229 --> 00:09:23,049 uh you know, 127 00:09:23,059 --> 00:09:24,750 with dosing information. 128 00:09:25,039 --> 00:09:41,989 And what we do is to uh uh provide guidance uh to clinician with uh respect of the best dose to give in order to achieve the best the level which is the most consistent with uh uh the disease control that needs to be achieved for the patient. 129 00:09:42,169 --> 00:09:43,729 Typically a vast majority, 130 00:09:43,739 --> 00:09:46,159 about two third of a third to two third, 131 00:09:46,169 --> 00:09:54,669 a third of patient uh tend to be uh uh unresponsive uh to this uh very expensive medication. 132 00:09:54,989 --> 00:09:57,960 Uh Not because they don't have the uh you know, 133 00:09:57,969 --> 00:09:59,289 typically because they have a, 134 00:09:59,299 --> 00:09:59,590 you know, 135 00:09:59,599 --> 00:10:05,599 pharmacokinetic uh suboptimal pharmacokinetic uh that makes them uh you know, 136 00:10:05,609 --> 00:10:09,440 unresponsive because uh not enough drug has been given. 137 00:10:09,450 --> 00:10:18,469 So what we do with a predictor test is to basically estimate the pa the pharmacokinetic uh parameter for the patient. 138 00:10:18,750 --> 00:10:24,729 And from then uh re report the best dose uh to give in order to achieve the, 139 00:10:24,760 --> 00:10:31,570 the level which is consistent with the uh the most uh uh effective disease control to be achieved for the patient. 140 00:10:32,169 --> 00:10:33,059 So we are offering, 141 00:10:33,070 --> 00:10:38,049 we have developed a test for the Infliximab as well as Adalimumab which is Humira, 142 00:10:38,909 --> 00:10:41,309 but these are antimony causes factor. 143 00:10:41,460 --> 00:10:49,549 And we are also developing the test for vidur as well as uh is that are widely used also in the treatment of, 144 00:10:49,559 --> 00:10:51,969 of uh inflammatory bubble disease. 145 00:10:51,979 --> 00:10:52,669 Wow, 146 00:10:52,679 --> 00:10:55,450 uh for MET is a suite of tests. 147 00:10:55,460 --> 00:11:00,940 Goes well beyond um the PGX testing that our audience is most familiar with, 148 00:11:01,299 --> 00:11:08,679 uh which typically only includes snips for cyp genes and some pharmacodynamic genes. 149 00:11:08,690 --> 00:11:31,424 This is really exciting um genes and biomarkers related to immunology are not commonly found in what I call the box PGX tests such as those uh made by large uh laboratory manufacturing companies um where the panel has a set number of genes and uh you know, 150 00:11:31,434 --> 00:11:36,054 it was developed by a larger laboratory for maybe smaller laboratories use. 151 00:11:36,729 --> 00:11:39,010 So my understanding, 152 00:11:39,020 --> 00:11:53,729 having talked with you extensively theory is that immunology has fewer PGX test available because it's actually more difficult say than oncology to research and develop tests. 153 00:11:53,739 --> 00:11:54,119 So, 154 00:11:54,130 --> 00:12:00,729 could you elaborate for our audience on the difficulties that are associated with immunology, 155 00:12:00,739 --> 00:12:05,830 research and developing tests uh for immunology versus say oncology? 156 00:12:06,330 --> 00:12:06,530 Yeah, 157 00:12:06,539 --> 00:12:07,049 sure. 158 00:12:07,059 --> 00:12:09,969 So in uh in immunology, 159 00:12:09,979 --> 00:12:11,590 as compared to oncology, 160 00:12:11,599 --> 00:12:17,169 there is no such a thing such as a somatic mutation where for example, 161 00:12:17,179 --> 00:12:18,429 you're gonna have a behalf, 162 00:12:18,440 --> 00:12:18,659 you know, 163 00:12:18,669 --> 00:12:20,349 that indicates that the patient, 164 00:12:20,679 --> 00:12:20,919 you know, 165 00:12:20,929 --> 00:12:25,239 is likely to benefit or not from some treatment in immunology. 166 00:12:25,250 --> 00:12:26,750 This is far more complicated, 167 00:12:26,760 --> 00:12:28,830 complicated for the reason, 168 00:12:29,239 --> 00:12:31,020 starting with uh the fact that, 169 00:12:31,030 --> 00:12:31,179 you know, 170 00:12:31,190 --> 00:12:36,219 the response to this uh medication uh are multifactorial. 171 00:12:36,260 --> 00:12:37,820 And the fact that uh you know, 172 00:12:37,830 --> 00:12:39,380 the mutation that uh the, 173 00:12:39,390 --> 00:12:39,619 the, 174 00:12:39,630 --> 00:12:45,190 the single nucleotide polymorphism in the GM line which uh uh you know, 175 00:12:45,200 --> 00:12:52,429 can potentially associate with uh with outcome uh uh uh uh a lo in advance, 176 00:12:52,440 --> 00:12:58,359 meaning that uh they're gonna have a weak association uh with a response to those medications. 177 00:12:58,369 --> 00:13:09,609 So there is a necessity in immunology to combine multiple genetic polymorphism together in order to achieve uh some uh performances characteristics that will make uh you know, 178 00:13:09,619 --> 00:13:09,859 the, 179 00:13:09,869 --> 00:13:10,380 the, 180 00:13:10,390 --> 00:13:10,520 the, 181 00:13:10,530 --> 00:13:13,219 the clinician uh you know, 182 00:13:13,419 --> 00:13:15,619 uh order the test and most importantly, 183 00:13:15,630 --> 00:13:15,840 the, 184 00:13:15,849 --> 00:13:16,179 the, 185 00:13:16,190 --> 00:13:17,739 the payer to pay for the test. 186 00:13:17,750 --> 00:13:20,469 So this field has been uh you know, 187 00:13:20,479 --> 00:13:20,679 is, 188 00:13:20,690 --> 00:13:21,705 is moving for, 189 00:13:21,715 --> 00:13:21,994 you know, 190 00:13:22,005 --> 00:13:24,575 there are some tests that are being developed right now. 191 00:13:24,924 --> 00:13:39,034 But the biggest challenge is to be able to achieve again the the threshold of uh of performance that makes the test is variable enough uh to be uh again ordered by the clinician and the utilize uh to the benefit of the patient. 192 00:13:39,659 --> 00:13:41,200 I couldn't agree with you more. 193 00:13:41,210 --> 00:13:53,489 Um I've worked on the payer side or market access side of pharmacogenomics and even uh with a box test for which there's um a lot of research data available, 194 00:13:53,500 --> 00:13:55,119 even with those, 195 00:13:55,130 --> 00:13:59,760 it's sometimes difficult uh to get payers um to see the value. 196 00:13:59,770 --> 00:14:01,640 So I absolutely agree with you. 197 00:14:01,940 --> 00:14:03,679 Um The fact that you guys are, 198 00:14:03,690 --> 00:14:11,789 are uh investing in producing the data necessary says a lot about your laboratory. 199 00:14:11,979 --> 00:14:12,559 Um you know, 200 00:14:12,570 --> 00:14:15,380 and how committed you are to this testing and, 201 00:14:15,390 --> 00:14:17,320 and how you believe in the testing. 202 00:14:18,039 --> 00:14:23,640 So I just want to make sure that our audience recognizes that, 203 00:14:24,359 --> 00:14:24,619 you know, 204 00:14:24,630 --> 00:14:31,820 Prometheus doesn't simply provide tests to determine if drugs for IBD will be effective and safe. 205 00:14:32,190 --> 00:14:36,900 Um And maybe what the dose of the drug should be for the patient, 206 00:14:36,909 --> 00:14:40,219 but you have that whole suite of tests. 207 00:14:40,229 --> 00:14:47,380 Um the diagnostic test for the differential diagnosis all the way through remission. 208 00:14:48,030 --> 00:14:53,390 So can you elaborate you elaborated on it some in the previous question? 209 00:14:53,400 --> 00:15:01,229 But um can you tell us the difference between how you had to actually develop the test? 210 00:15:01,520 --> 00:15:02,530 Um You didn't, 211 00:15:02,539 --> 00:15:03,059 in other words, 212 00:15:03,070 --> 00:15:10,659 purchase a test from another manufacturer with the biomarkers that you include in your testing. 213 00:15:10,669 --> 00:15:16,830 Can you elaborate on how much more difficult it is to to develop a test from scratch? 214 00:15:18,169 --> 00:15:18,320 Yeah, 215 00:15:18,330 --> 00:15:18,659 sure. 216 00:15:18,669 --> 00:15:18,809 I mean, 217 00:15:18,820 --> 00:15:22,070 this is this is challenging for multiple and first of all, 218 00:15:22,080 --> 00:15:23,130 you need to have the, 219 00:15:23,419 --> 00:15:27,450 you need to have a clinical data set available with specimen available. 220 00:15:27,460 --> 00:15:28,159 Uh you know, 221 00:15:28,169 --> 00:15:28,780 in front, 222 00:15:28,859 --> 00:15:29,770 obviously, 223 00:15:29,859 --> 00:15:30,890 available. 224 00:15:31,200 --> 00:15:35,890 Uh So we are leveraging a pro meters a large bi bank of specimen. 225 00:15:36,299 --> 00:15:37,190 Uh as I said, 226 00:15:37,200 --> 00:15:39,719 Prometheus has been founded 25 years ago. 227 00:15:39,729 --> 00:15:40,599 So over the, 228 00:15:40,760 --> 00:15:41,919 the past two decades, 229 00:15:41,929 --> 00:15:54,849 we have been able to assemble a large uh substrate of data and specimen which we are uh uh using to uh uh establish our proof of concept if you will. 230 00:15:54,859 --> 00:16:07,559 And then when we have uh identify some genetic polymorphism that are uh adequately uh associated with uh uh disease outcome and disease progression as well as uh toxicity. 231 00:16:07,969 --> 00:16:11,469 Then we are entering validation phase where we are uh you know, 232 00:16:11,570 --> 00:16:14,789 using validation cohorts where we are again, 233 00:16:14,969 --> 00:16:22,630 combining multiple modalities together uh patient demographic as well as genetic marker together with theological marker. 234 00:16:22,640 --> 00:16:23,190 Actually, 235 00:16:23,500 --> 00:16:27,419 to come up with some Multivariate models that are uh again, 236 00:16:27,429 --> 00:16:39,250 bringing the performances characteristics of the pharmacogenomic test or its combination with our marker to the level where it's supposed to be in the first place to meet uh uh payer. 237 00:16:39,650 --> 00:16:41,190 And uh obviously, 238 00:16:41,200 --> 00:16:41,760 again, 239 00:16:41,770 --> 00:16:45,320 the patient uh to the benefit of the patient and to, 240 00:16:45,330 --> 00:16:46,619 to improve its outcome, 241 00:16:46,739 --> 00:16:47,429 the outcome. 242 00:16:48,340 --> 00:16:53,380 I think what you're describing really is the future of pharmacogenomics. 243 00:16:53,390 --> 00:16:54,599 Um In other words, 244 00:16:54,609 --> 00:17:03,419 not singing out pharmacogenomics as you know the end all and be all in the treatment paradigm. 245 00:17:03,559 --> 00:17:08,040 But using a PGX test in combination with, 246 00:17:08,050 --> 00:17:09,069 like you mentioned, 247 00:17:09,250 --> 00:17:11,160 other serological tests, 248 00:17:11,170 --> 00:17:12,959 maybe other genetic tests. 249 00:17:13,290 --> 00:17:14,890 Um But you know, 250 00:17:14,900 --> 00:17:25,869 I think what we want our audience to really wrap their heads around is that PGX is just a piece of that larger puzzle um from diagnosis to treatment to, 251 00:17:25,880 --> 00:17:26,910 to remission. 252 00:17:27,239 --> 00:17:29,880 So I think you guys are absolutely, 253 00:17:29,890 --> 00:17:31,579 you're already in the future. 254 00:17:31,589 --> 00:17:32,849 In other words, 255 00:17:32,859 --> 00:17:33,130 you know, 256 00:17:33,140 --> 00:17:39,689 you're already providing all these different uh tests um like you mentioned to, 257 00:17:39,699 --> 00:17:44,310 to facilitate from diagnosis to remission to remission. 258 00:17:44,660 --> 00:17:45,520 That's correct. 259 00:17:45,530 --> 00:17:45,829 Yeah. 260 00:17:46,349 --> 00:17:55,089 So um you've given us so much great information about uh the tests that that you guys offer. 261 00:17:55,329 --> 00:18:02,060 Can you explain to our audience um your newest test? 262 00:18:02,069 --> 00:18:03,859 Uh the responder test. 263 00:18:04,150 --> 00:18:12,979 And um what role it will play in the paradigm from the diagnosis of IBD to remission? 264 00:18:14,050 --> 00:18:14,260 Yeah, 265 00:18:14,270 --> 00:18:14,760 sure. 266 00:18:14,770 --> 00:18:15,569 So we, 267 00:18:15,579 --> 00:18:18,069 we are doing things a little bit different than other. 268 00:18:18,079 --> 00:18:19,489 We do believe that uh you know, 269 00:18:19,500 --> 00:18:21,449 the it has to be simple. 270 00:18:21,459 --> 00:18:24,189 Uh uh We can obviously construct some very, 271 00:18:24,199 --> 00:18:33,530 very complex algorithm and there are some tests that do that with a very sophisticated machine learning based tools that are available using neural networks, 272 00:18:33,540 --> 00:18:33,729 you know, 273 00:18:33,739 --> 00:18:34,790 those sorts of things. 274 00:18:34,800 --> 00:18:39,729 But we have taken on a different approach where with the responder test, 275 00:18:39,739 --> 00:18:40,329 we are basically, 276 00:18:40,339 --> 00:18:45,160 we are taking an approach which is very simple to address the first and foremost. 277 00:18:45,170 --> 00:18:53,020 Most important aspect of responding uh predicting response to uh to medication is the pharmacokinetics. 278 00:18:53,280 --> 00:19:03,250 Uh You cannot be responding to a drug if the drug is not given and you obviously cannot respond to a drug if the drug is not metabolized adequately. 279 00:19:03,359 --> 00:19:06,349 And this is what we are doing with the responder test. 280 00:19:06,579 --> 00:19:09,010 We are addressing some uh uh you know, 281 00:19:09,020 --> 00:19:11,630 fundamental issues with those uh biologist, 282 00:19:11,640 --> 00:19:12,410 for example, 283 00:19:12,660 --> 00:19:15,170 uh the anti tumor necrosis factors. 284 00:19:15,180 --> 00:19:15,650 So, 285 00:19:15,750 --> 00:19:19,199 such as uh Infliximab and Adalimumab, 286 00:19:19,209 --> 00:19:23,050 it is well known uh that uh uh those drugs, 287 00:19:23,060 --> 00:19:25,689 first of all are prone to immunization. 288 00:19:25,989 --> 00:19:36,949 Uh Meaning that uh uh the drug itself uh is recognized by the immune system uh and digested by the antigen presenting cells. 289 00:19:36,959 --> 00:19:42,209 If you will uh where you gonna have uh uh an immune uh uh response, 290 00:19:42,380 --> 00:19:56,979 uh mounted a cancer drug to produce uh immunogen that will severely impact its pharmacokinetics where the labels will be inadequate to produce uh the desired uh anti-inflammatory effects. 291 00:19:56,989 --> 00:19:57,150 So, 292 00:19:57,160 --> 00:19:58,890 we are with the risk conductors, 293 00:19:58,900 --> 00:20:01,040 we are combining two things together. 294 00:20:01,189 --> 00:20:07,959 First of all is the genetic test itself which uh predicts the risk of immun immunization. 295 00:20:07,969 --> 00:20:18,010 The name of the test is on HL A uh DQ A 105 ali uh that uh uh promotes the presentation of the, 296 00:20:18,020 --> 00:20:19,130 of the, 297 00:20:19,140 --> 00:20:19,910 of Infliximab, 298 00:20:20,010 --> 00:20:20,750 for example, 299 00:20:20,760 --> 00:20:32,130 to the T cell repertoire in order to uh promote the Ronon expansion and the formation of the anti antibodies together with uh another dimension which is the clearance, 300 00:20:32,140 --> 00:20:33,670 which is as important. 301 00:20:33,949 --> 00:20:36,209 Uh One of the key issue is the, 302 00:20:36,219 --> 00:20:36,770 the, 303 00:20:36,780 --> 00:20:41,239 the monoclonal antibodies and uh such as Infliximab or Adalimumab. 304 00:20:41,329 --> 00:20:42,280 But in fact, 305 00:20:42,290 --> 00:20:45,890 a neon antibodies that those drugs are uh you know, 306 00:20:45,900 --> 00:20:49,010 cleared and consumed uh from the, 307 00:20:49,020 --> 00:20:50,949 from the central compartment if you will, 308 00:20:50,959 --> 00:20:54,520 since we are doing a little bit of uh uh pharmacokinetics here. 309 00:20:54,530 --> 00:20:56,020 And uh uh you know, 310 00:20:56,030 --> 00:21:06,670 if the patient present who is uh a high degree of inflammatory burden is gonna have uh the patient will have a high clearance and that's gonna worsen uh in the, 311 00:21:06,680 --> 00:21:13,939 in the presence again of the HL AD Q A 105 genetic marker that uh associate with uh immunization. 312 00:21:13,949 --> 00:21:16,859 So I but this is a combination of both, 313 00:21:17,199 --> 00:21:19,359 these are the predictive factors of pharmacokinetic, 314 00:21:20,359 --> 00:21:38,209 which we combine together where the patient presenting with a risk of immunization as well as accelerated clearance due to the fact that the patient has high inflammation or due to the fact that they are so intrinsic pharmacokinetic properties that makes that the patient, 315 00:21:38,219 --> 00:21:38,300 you know, 316 00:21:38,310 --> 00:21:39,479 will clear the drug very, 317 00:21:39,489 --> 00:21:40,260 very fast. 318 00:21:40,560 --> 00:21:41,670 For example, 319 00:21:41,680 --> 00:21:46,819 due to the inefficient uh recirculation of the drug itself with the new, 320 00:21:46,869 --> 00:21:46,930 the, 321 00:21:46,939 --> 00:21:50,599 the the in the reticular on the system. 322 00:21:50,920 --> 00:21:51,619 Together, 323 00:21:51,630 --> 00:22:02,109 those patients presenting with uh uh together these uh poor prognostic factor of pharmacokinetic origin will tend to be severely underdose, 324 00:22:02,380 --> 00:22:06,719 will not be responding to the drug uh adequately as and they, 325 00:22:06,729 --> 00:22:10,719 and they probably should in the first place if you are able to address uh you know, 326 00:22:10,729 --> 00:22:12,270 the the the exposure. 327 00:22:12,439 --> 00:22:14,079 So what we do with this test, 328 00:22:14,089 --> 00:22:21,640 we will be able to inform uh the clinic that the patient is at risk of achieving, 329 00:22:21,650 --> 00:22:30,829 of achieving suboptimal pharmacokinetics and therefore being able to adjust the dose uh uh to start with more adequately. 330 00:22:30,839 --> 00:22:38,650 So that the the the proper uh exposure is achieved uh during induction to again to, 331 00:22:38,660 --> 00:22:39,040 to, 332 00:22:39,050 --> 00:22:39,380 to, 333 00:22:39,390 --> 00:22:40,890 to achieve a better outcome. 334 00:22:41,040 --> 00:22:47,270 And I think the pharmacist will have a very important role to play here in terms of absolutely, 335 00:22:47,280 --> 00:22:51,239 that information is priceless in the management of these medications. 336 00:22:51,250 --> 00:22:54,930 So thanks for elaborating on that. 337 00:22:56,010 --> 00:22:59,040 And if I may add in our previous conversation, 338 00:22:59,050 --> 00:23:00,810 uh before the recording of podcast, 339 00:23:00,819 --> 00:23:08,869 we had discussed um you guys' robust platform for collaborating with payers to obtain market access and reimbursements for the test. 340 00:23:09,109 --> 00:23:14,109 But without stealing the Thunder from uh Prometheus market access and reimbursement team, 341 00:23:14,199 --> 00:23:22,619 can you please uh briefly detail how Prometheus has proactively worked with payers to solve the problem. 342 00:23:22,920 --> 00:23:27,349 Um the population health problem by building the evidence payers want, 343 00:23:27,359 --> 00:23:41,170 want to see um about your test before you go to the market and then build the test and then hope the payers will see the value and the result and then that will improve the market access and reimbursement for your um precision medicine test. 344 00:23:42,160 --> 00:23:42,339 Yeah. 345 00:23:42,349 --> 00:23:43,180 So briefly I can, 346 00:23:43,189 --> 00:23:43,579 I'm, 347 00:23:43,589 --> 00:23:46,619 I'm probably not the right person to answer that question. 348 00:23:46,630 --> 00:23:47,369 We have a very, 349 00:23:47,380 --> 00:23:52,400 very efficient market access group uh uh pro meters that does a splendid job. 350 00:23:52,410 --> 00:23:59,780 But uh uh uh what I can tell you that we have an evidence uh uh development plan in place where we, 351 00:23:59,790 --> 00:24:14,000 we are establishing the clinical utility of our testing solution by demonstrating uh the payer value uh with respect of uh patient management and uh uh and the, 352 00:24:14,010 --> 00:24:16,630 and the impact of our technology on the, 353 00:24:16,640 --> 00:24:18,119 on physician behavior. 354 00:24:18,430 --> 00:24:21,319 Uh We have uh uh already uh you know, 355 00:24:21,329 --> 00:24:25,160 commercialized uh two of those tests for which we have initiated, 356 00:24:25,170 --> 00:24:29,040 initiated the Power studies uh that uh uh you know, 357 00:24:29,050 --> 00:24:32,000 already provide uh you know, 358 00:24:32,104 --> 00:24:34,484 differentiated and the value to, 359 00:24:34,494 --> 00:24:35,915 to the payer where we are, 360 00:24:35,925 --> 00:24:36,025 the, 361 00:24:36,035 --> 00:24:46,005 the clinicians are basically using our technology to make treatment decision uh as well as uh some prospective clinicality study which we are initiating, 362 00:24:46,145 --> 00:24:47,555 initiating to. 363 00:24:47,564 --> 00:24:48,574 Um uh again, 364 00:24:48,584 --> 00:24:49,425 demonstrate the, 365 00:24:49,435 --> 00:24:49,915 the, 366 00:24:49,925 --> 00:24:50,244 the, 367 00:24:50,255 --> 00:24:53,594 the payer value you uh uh we can certainly follow up with, 368 00:24:53,604 --> 00:24:58,755 uh you can certainly follow up with our market access group uh uh as appropriate there. 369 00:24:58,765 --> 00:25:00,765 Uh They can fill you with more information. 370 00:25:01,349 --> 00:25:01,589 No, 371 00:25:01,599 --> 00:25:02,520 that totally makes sense. 372 00:25:02,530 --> 00:25:03,310 That totally makes sense. 373 00:25:03,319 --> 00:25:10,890 But um we're excited that you're also farm d So how did you get to this role of outside the box path? 374 00:25:10,900 --> 00:25:11,550 There? 375 00:25:11,640 --> 00:25:17,530 There may be a pharmacist student or pharmacist wanting to switch or transition into a role such as yours, 376 00:25:17,540 --> 00:25:19,609 which is a Chief Scientific Officer. 377 00:25:19,619 --> 00:25:20,609 I want to learn more. 378 00:25:20,619 --> 00:25:23,920 So how would you um can you talk a little bit about that? 379 00:25:24,560 --> 00:25:24,780 Well, 380 00:25:24,790 --> 00:25:26,270 we are clinical laboratories. 381 00:25:26,280 --> 00:25:29,400 So in order to uh uh to be in my role, 382 00:25:29,410 --> 00:25:34,020 you need to have uh uh you need to have expertise in clinical laboratory science. 383 00:25:34,030 --> 00:25:36,140 So for the students is basically, 384 00:25:36,150 --> 00:25:36,300 you know, 385 00:25:36,310 --> 00:25:40,770 to do the family degree and then complete the family degree with uh a doctorate, 386 00:25:40,780 --> 00:25:40,930 you know, 387 00:25:40,939 --> 00:25:44,260 which is uh focus on clinical laboratory science. 388 00:25:44,270 --> 00:25:46,079 So you can achieve uh uh you know, 389 00:25:46,089 --> 00:25:47,640 the all the elements you need to be, 390 00:25:47,650 --> 00:25:48,219 for example, 391 00:25:48,229 --> 00:25:53,189 board certified uh as uh as as medical laboratory director. 392 00:25:53,199 --> 00:25:55,160 So you can uh uh so, 393 00:25:55,170 --> 00:25:55,589 uh yeah, 394 00:25:55,599 --> 00:25:56,030 this is, 395 00:25:56,040 --> 00:25:56,400 this is, 396 00:25:56,410 --> 00:25:57,209 this is uh you know, 397 00:25:57,219 --> 00:25:59,160 a great opportunity I think for pharmacies, 398 00:25:59,170 --> 00:26:10,800 there is an absolute need to uh have the clinical pharmacist provide uh uh drug information to healthcare professional as well as uh assist patient with the monitoring of their disease, 399 00:26:10,810 --> 00:26:15,229 the effectiveness of the therapy and um and uh you know, 400 00:26:15,239 --> 00:26:16,060 monitoring the, 401 00:26:16,069 --> 00:26:20,969 the side effect and the toxicity from uh from those uh those medication. 402 00:26:24,650 --> 00:26:24,959 Well, 403 00:26:24,969 --> 00:26:32,119 the I know our audience is going to have uh additional questions for you. 404 00:26:32,130 --> 00:26:32,540 I mean, 405 00:26:32,989 --> 00:26:35,609 you've provided them with so much great information, 406 00:26:35,619 --> 00:26:44,959 but it's only the beginning of what they could possibly learn um about um the testing that you do for IBD and, 407 00:26:44,969 --> 00:26:46,729 and even your career path. 408 00:26:47,050 --> 00:26:47,530 So, 409 00:26:47,540 --> 00:26:49,300 if you wouldn't mind telling us, 410 00:26:49,310 --> 00:26:51,359 um because we have to wrap up, 411 00:26:51,369 --> 00:26:52,670 unfortunately, 412 00:26:53,150 --> 00:26:55,810 this episode of the podcast, 413 00:26:55,819 --> 00:27:00,250 uh could you tell us how our audience members might be able to contact you directly. 414 00:27:01,260 --> 00:27:01,449 Yeah, 415 00:27:01,459 --> 00:27:07,079 I can be contacted on my uh on my email at TT W at como slab dot com. 416 00:27:07,949 --> 00:27:08,810 All right. 417 00:27:09,069 --> 00:27:09,300 Well, 418 00:27:09,310 --> 00:27:14,290 thank you again so much uh for joining us on this episode. 419 00:27:14,300 --> 00:27:15,290 We really, 420 00:27:15,300 --> 00:27:29,530 really hope that our listeners um ideas of not only what PGX can be but how PGX can be utilized in a comprehensive testing suite. 421 00:27:29,709 --> 00:27:35,670 We really hope that our a our audience will um listen in and learn this information. 422 00:27:36,280 --> 00:27:37,869 Um And to our audience, 423 00:27:37,880 --> 00:27:39,439 thank you for tuning in. 424 00:27:39,449 --> 00:27:42,619 We really hope that you've learned from this episode. 425 00:27:43,130 --> 00:27:46,339 Uh We do a whole lot of PG Xing here on this podcast. 426 00:27:46,349 --> 00:27:48,380 We talk about PGX Science, 427 00:27:48,390 --> 00:27:52,030 clinical application and the business of PGX. 428 00:27:52,260 --> 00:27:54,880 So we'd love to hear about from you. 429 00:27:55,099 --> 00:27:56,479 I love to hear from you. 430 00:27:56,489 --> 00:27:58,439 Um What can we teach you? 431 00:27:58,449 --> 00:28:00,920 What more can we teach you through our podcast? 432 00:28:00,930 --> 00:28:12,349 So please drop us a message on linkedin and let us know and please share this link to this podcast link episode with everyone so they can tune in and listen to the PGX for promises podcast. 433 00:28:12,520 --> 00:28:15,369 Leave us a review on Apple podcast or Spotify. 434 00:28:15,459 --> 00:28:18,130 And you can also visit us on PGX four, 435 00:28:18,140 --> 00:28:22,989 the number four Rx dot com to listen to all our other episodes. 436 00:28:23,000 --> 00:28:23,079 Well, 437 00:28:23,089 --> 00:28:23,790 thank you. 438 00:28:24,199 --> 00:28:28,750 Thanks for your interest in PGX and for spending some time with us. 439 00:28:28,760 --> 00:28:35,670 Please share this podcast and leave us a review on Apple podcasts or Spotify for all of our episodes. 440 00:28:35,680 --> 00:28:39,390 Please visit PGX for Rx dot com. 441 00:28:39,569 --> 00:28:43,380 That's PGX for Rx dot com.

From PharmD to Pharmacogenomics Test Developer: Dr. Thierry Dervieux's Story of Revolutionizing Healthcare Through Precision Medicine for Immune Modulated Inflammatory Diseases | PGx For Pharmacists

Pharmacy Podcast Network

Play Episode Listen Later Oct 27, 2023 28:46 Transcription Available

Becky Winslow, BS, PharmD Host and Pharmacogenomics Medical Science Liaison; Behnaz Sarrami, MS, PharmD, Host and Pharmacogenomics Medical Science Liaison; Thierry Dervieux, PharmD, PhD, Chief Scientific Officer at Prometheus Laboratories In this episode of the PGX for Pharmacists Podcast, Dr. Thierry Dervieux, Dr. Behnaz Sarrami, and I discuss Dr. Dervieux's career as a PharmD, PhD, and chief scientific officer who has designed a pharmacogenomics test prescribers may use to optimize biosimilars for autoimmune gastrointestinal diseases. Dr. Dervieux will illustrate to our audience pharmacogenomics' potential beyond Tier 1 and 2 genetic testing by describing the clinical validity and utility of his laboratory's suite of tests in the autoimmune gastrointestinal disease diagnosis and treatment market. Behnaz and I hope this episode will inspire pharmacists interested in pharmacogenomics to think beyond the boxed PGx test most laboratories offer when they think about PGx and consider all the biological systems in which genetics impacts drugs' efficacy and safety. Disclaimer: Behnaz Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of Castle Biosciences, Inc. Becky Disclaimer: These are my personal views and opinions, and I am not speaking on behalf of any other entity. Transcription: 1 00:00:06,190 --> 00:00:19,620 You're listening to the Pharmacy podcast Network in a world where one size fits all medications dominate the pharmaceutical industry. 2 00:00:20,079 --> 00:00:24,750 Precision medicine brings a ray of hope for those seeking customized health care. 3 00:00:25,350 --> 00:00:32,830 Pharmacists have a unique opportunity to help people in need of specialized testing to ensure medications work as intended. 4 00:00:33,540 --> 00:00:44,680 Welcome to PGX for pharmacists where we unravel the wonders of precision medicine and its potential to revolutionize the way we approach pharmacy care. 5 00:00:45,169 --> 00:00:52,790 Get ready to uncover the secrets behind pharmacogenomics and how it's transforming lives one genome at a time. 6 00:00:52,799 --> 00:00:53,189 Hello, 7 00:00:53,200 --> 00:00:53,950 everyone. 8 00:00:54,159 --> 00:00:55,080 I'm your host, 9 00:00:55,090 --> 00:00:56,389 Doctor Becky Winslow. 10 00:00:56,409 --> 00:01:09,860 And you're listening to the PGX for Pharmacist podcast that we magazine recognized in 2021 as the ninth most listened to genetics podcasts in the world on the PGX for Pharmacist podcast. 11 00:01:09,870 --> 00:01:16,690 We explore all things pharmacogenomics related and our mission is to educate and advocate for PGX. 12 00:01:16,769 --> 00:01:23,849 We accomplish this mission through exclusive interviews with highly qualified and well experienced pharmacogenomics. 13 00:01:23,860 --> 00:01:29,720 Industry leaders such as today's special guest and my name is Baas Sami, 14 00:01:29,730 --> 00:01:32,739 the co-host of PGX for Pharms podcast, 15 00:01:32,750 --> 00:01:33,860 Pharmacogenomics, 16 00:01:33,870 --> 00:01:36,819 medical science liaison and a mentor to pharmacist. 17 00:01:36,889 --> 00:01:40,239 Connect with us on linkedin and let's get a conversation going. 18 00:01:40,269 --> 00:01:46,720 We want to hear from you and how you're impacting pharmacogenomic stakeholders and what you have learned throughout your journey. 19 00:01:48,510 --> 00:01:49,010 Ok. 20 00:01:49,019 --> 00:01:50,819 So without any further ado, 21 00:01:50,839 --> 00:01:54,769 I'm extremely pleased to introduce to our audience. 22 00:01:54,919 --> 00:01:56,059 Doctor Theory Devo, 23 00:01:57,239 --> 00:02:01,129 the Chief Scientific Officer at Prometheus Laboratories, 24 00:02:01,139 --> 00:02:08,139 and Perme Prometheus Laboratories is a reference clinical laboratory that's focused on the diagnosis, 25 00:02:08,149 --> 00:02:13,330 prognosis and monitoring of immune mediated inflammatory diseases. 26 00:02:13,970 --> 00:02:14,229 So, 27 00:02:14,240 --> 00:02:14,649 thank you, 28 00:02:14,660 --> 00:02:17,759 Doctor De for joining us on the podcast. 29 00:02:17,770 --> 00:02:18,589 Today. 30 00:02:18,600 --> 00:02:23,190 I'm excited to share your and Prometheus's story with our audience. 31 00:02:23,649 --> 00:02:25,630 Um in particular, 32 00:02:25,639 --> 00:02:45,369 I'm excited about you sharing your career journey as a farm D phd and Chief scientific officer and designer of the Predictor PK AD A which is a precision guided dosing test for the optimization of Humira Remicade and their bio cylinders. 33 00:02:46,119 --> 00:02:46,449 So, 34 00:02:46,460 --> 00:03:04,220 one of Bana's and my main goals for this episode of the PGX for Pharmacist podcast is to expand our audience's notion of what a PGX test looks like and to inspire them to think bigger than the traditional box PGX test. 35 00:03:04,229 --> 00:03:08,020 Most of them or most of you are uh familiar with. 36 00:03:09,020 --> 00:03:09,429 So, 37 00:03:09,440 --> 00:03:22,179 Doctor D uh I'd like to start the podcast by having our guests um introduce themselves and elaborate on how you are a pharmacogenomics expert. 38 00:03:23,619 --> 00:03:23,800 Yeah, 39 00:03:23,809 --> 00:03:24,250 thank you, 40 00:03:24,259 --> 00:03:25,759 Becky for having me. 41 00:03:25,770 --> 00:03:26,850 Uh uh Yes. 42 00:03:26,860 --> 00:03:27,289 So I am a, 43 00:03:27,300 --> 00:03:30,820 I am a pharmacist uh with uh a family who is a, 44 00:03:30,830 --> 00:03:33,039 a doctorate in pharmacokinetics. 45 00:03:33,539 --> 00:03:44,520 Uh I completed my studies in France and I came as a postdoc uh fellow uh to work in the United States about 20 years ago to work on the pharmacogenomic of anti cancer agents, 46 00:03:44,929 --> 00:03:49,160 uh primarily uh six Maturin as well as methotrexate. 47 00:03:49,169 --> 00:03:50,550 After my post doc, 48 00:03:50,770 --> 00:03:52,960 uh I moved uh in industry for promet. 49 00:03:53,490 --> 00:04:01,429 So I have a large experience in uh uh the implementation of pharmacogenetics testing in immune mediated inflammatory disease. 50 00:04:01,509 --> 00:04:12,550 Our lab Rome was the first uh clinical laboratory in the United States to offer the fin uh metyl transfer genotyping as well as the thin metabolites. 51 00:04:12,559 --> 00:04:13,029 So, 52 00:04:13,050 --> 00:04:21,989 uh uh of uh of 70 publications in the field and uh I'm very uh very excited to have uh to be on the postcard with you uh uh today. 53 00:04:23,660 --> 00:04:24,220 All right. 54 00:04:24,230 --> 00:04:27,359 So thank you for qualifying yourself as an expert. 55 00:04:27,369 --> 00:04:27,619 So, 56 00:04:27,630 --> 00:04:32,839 let's jump right in and delve into your current PGX work. 57 00:04:32,850 --> 00:04:33,279 So, 58 00:04:33,489 --> 00:04:36,540 if you'll tell us um a little about Prometheus, 59 00:04:36,549 --> 00:04:38,000 specifically, 60 00:04:38,010 --> 00:04:40,350 what is Prometheus's mission? 61 00:04:40,359 --> 00:04:43,799 And how are you guys going about accomplishing your mission? 62 00:04:44,760 --> 00:04:44,980 Yeah, 63 00:04:44,989 --> 00:04:45,700 sure. 64 00:04:45,709 --> 00:04:47,459 Uh So Promet is a, 65 00:04:47,470 --> 00:04:52,790 is a reference uh clinical laboratory based in Southern California in San Diego. 66 00:04:53,230 --> 00:04:56,809 Uh The company has been there for uh over 25 years. 67 00:04:56,820 --> 00:05:03,950 We are uh specialize in the differential diagnosis of autoimmune G I disease uh disorders, 68 00:05:04,059 --> 00:05:06,019 uh gastrointestinal disorder, 69 00:05:06,230 --> 00:05:08,619 uh and inflammatory bowel disease. 70 00:05:08,980 --> 00:05:10,299 And over the years, 71 00:05:10,309 --> 00:05:16,600 we have developed a portfolio of a differentiated solution to facilitate the diagnosis, 72 00:05:16,609 --> 00:05:17,470 the prognosis, 73 00:05:17,480 --> 00:05:18,429 the monitoring, 74 00:05:18,660 --> 00:05:21,910 as well as therapy selection with pharmacogenetics testing, 75 00:05:21,920 --> 00:05:24,730 which we are offering to our clinical laboratory. 76 00:05:24,829 --> 00:05:26,350 And most importantly, 77 00:05:26,410 --> 00:05:27,299 uh recently, 78 00:05:27,309 --> 00:05:35,660 we are uh uh developing some uh uh testing solution with the credit topic care test to optimize treatment to uh biologics. 79 00:05:36,470 --> 00:05:37,130 Ok. 80 00:05:37,140 --> 00:05:37,329 Well, 81 00:05:37,339 --> 00:05:37,450 that, 82 00:05:37,459 --> 00:05:38,049 that's great. 83 00:05:38,059 --> 00:05:46,100 Can you also tell us uh about the Prois Library of Precision Medicine Tests for inflammatory bowel disease for patients? 84 00:05:46,109 --> 00:05:49,230 how they benefit medication therapy management. 85 00:05:49,239 --> 00:05:56,429 Stakeholders across the IB DS patients journey from diagnosis to treatment to disease, 86 00:05:56,440 --> 00:06:02,049 monitoring through remission and how they differ from other lab tests for IBD and his treatments. 87 00:06:02,709 --> 00:06:03,209 Yes. 88 00:06:03,220 --> 00:06:03,369 So, 89 00:06:03,380 --> 00:06:04,399 so we uh our, 90 00:06:04,410 --> 00:06:10,100 our clinical laboratory offers some uh highly specialized test to facilitate the, 91 00:06:10,109 --> 00:06:16,779 the diagnostic of uh to facilitate the differential diagnosis of uh uh inflammatory bowel disease. 92 00:06:16,790 --> 00:06:22,359 So we are following uh testing solution with uh serological testing, 93 00:06:22,529 --> 00:06:23,799 for example, 94 00:06:23,809 --> 00:06:38,410 uh uh piana as as as well as uh macro microbial uh uh antibodies that are present uh uh in Crohn's disease as well as uh over uh auto uh auto antibodies that are present in er colitis. 95 00:06:39,339 --> 00:06:43,684 These are conditions that are uh uh somewhat difficult to treat. 96 00:06:43,704 --> 00:06:49,994 Uh And uh we are uh uh offering those tests to uh help uh gastroenterologist. 97 00:06:50,015 --> 00:06:51,114 Uh uh first of all, 98 00:06:51,125 --> 00:07:03,434 to establish a differential diagnosis of IBD as compared to other uh condition typically uh uh irritable bowel syndrome as well as over gastrointestinal disorder. 99 00:07:03,445 --> 00:07:05,635 When the diagnostic is established, 100 00:07:05,910 --> 00:07:31,839 uh we offer uh testing to uh establish a prognosis where we're gonna in inform the clinician that the patient has a more aggressive uh disease that will require more aggressive treatment where uh we can uh provide the testing solution to initiate uh uh the most appropriate therapy for uh for the patient uh with uh a testing where we are uh basically uh you know, 101 00:07:31,850 --> 00:07:36,559 establish de determining some genotyping with the fit transferal genotyping. 102 00:07:36,570 --> 00:07:37,279 For example, 103 00:07:37,290 --> 00:07:40,250 where we can uh indicate that the patient is, 104 00:07:40,260 --> 00:07:45,079 is likely uh to present with a side effect to those medication. 105 00:07:45,399 --> 00:07:46,170 And once you know, 106 00:07:46,179 --> 00:07:47,799 the the treatment is initiative, 107 00:07:47,809 --> 00:08:16,089 we have a portfolio of solution uh to facilitate the monitoring of the disease of the inflammatory bowel disease as well as the dosing optimization with uh uh the answer test which uh measure blood level uh for uh uh monoclonal antibodies that are indicated in the treatment of IB start with starting with Infliximab Adalimumab as well as uh Tein and vidal. 108 00:08:16,980 --> 00:08:24,040 So we have a comprehensive portfolio to uh to surround the clinician with uh a variety of testing solution. 109 00:08:24,049 --> 00:08:30,250 With our goal being to improve the uh the outcome uh of patients with uh with diabetes. 110 00:08:30,260 --> 00:08:34,520 And I think that the pharmacist has a very important role to play from that perspective. 111 00:08:35,179 --> 00:08:36,039 So theory, 112 00:08:36,049 --> 00:08:40,239 could you elaborate for us more on the predictor test? 113 00:08:40,249 --> 00:08:42,758 Um especially since you designed that test, 114 00:08:42,768 --> 00:08:44,218 we'd really like to know, 115 00:08:44,489 --> 00:08:45,039 um you know, 116 00:08:45,049 --> 00:08:49,638 what did that take and what role does it play in your suite of testing? 117 00:08:51,049 --> 00:08:51,270 Yeah. 118 00:08:51,280 --> 00:08:51,890 Sure. 119 00:08:51,900 --> 00:08:52,510 So the, 120 00:08:52,520 --> 00:08:52,570 the, 121 00:08:52,580 --> 00:08:52,989 the, 122 00:08:53,000 --> 00:08:53,229 the, 123 00:08:53,239 --> 00:08:59,960 the predictor test is uh uh is uh is utilized when the patient is receiving treatment. 124 00:09:00,280 --> 00:09:18,190 It's been speci specifically designed to optimize uh biological uh uh disease modifiers such as Infliximab adalimumab that are co therapies in the treatment of inflammatory bowel disease as well as other immune uh mediated inflammatory. 125 00:09:18,200 --> 00:09:21,549 This is what the test does is to you connect the blood specimen, 126 00:09:22,229 --> 00:09:23,049 uh you know, 127 00:09:23,059 --> 00:09:24,750 with dosing information. 128 00:09:25,039 --> 00:09:41,989 And what we do is to uh uh provide guidance uh to clinician with uh respect of the best dose to give in order to achieve the best the level which is the most consistent with uh uh the disease control that needs to be achieved for the patient. 129 00:09:42,169 --> 00:09:43,729 Typically a vast majority, 130 00:09:43,739 --> 00:09:46,159 about two third of a third to two third, 131 00:09:46,169 --> 00:09:54,669 a third of patient uh tend to be uh uh unresponsive uh to this uh very expensive medication. 132 00:09:54,989 --> 00:09:57,960 Uh Not because they don't have the uh you know, 133 00:09:57,969 --> 00:09:59,289 typically because they have a, 134 00:09:59,299 --> 00:09:59,590 you know, 135 00:09:59,599 --> 00:10:05,599 pharmacokinetic uh suboptimal pharmacokinetic uh that makes them uh you know, 136 00:10:05,609 --> 00:10:09,440 unresponsive because uh not enough drug has been given. 137 00:10:09,450 --> 00:10:18,469 So what we do with a predictor test is to basically estimate the pa the pharmacokinetic uh parameter for the patient. 138 00:10:18,750 --> 00:10:24,729 And from then uh re report the best dose uh to give in order to achieve the, 139 00:10:24,760 --> 00:10:31,570 the level which is consistent with the uh the most uh uh effective disease control to be achieved for the patient. 140 00:10:32,169 --> 00:10:33,059 So we are offering, 141 00:10:33,070 --> 00:10:38,049 we have developed a test for the Infliximab as well as Adalimumab which is Humira, 142 00:10:38,909 --> 00:10:41,309 but these are antimony causes factor. 143 00:10:41,460 --> 00:10:49,549 And we are also developing the test for vidur as well as uh is that are widely used also in the treatment of, 144 00:10:49,559 --> 00:10:51,969 of uh inflammatory bubble disease. 145 00:10:51,979 --> 00:10:52,669 Wow, 146 00:10:52,679 --> 00:10:55,450 uh for MET is a suite of tests. 147 00:10:55,460 --> 00:11:00,940 Goes well beyond um the PGX testing that our audience is most familiar with, 148 00:11:01,299 --> 00:11:08,679 uh which typically only includes snips for cyp genes and some pharmacodynamic genes. 149 00:11:08,690 --> 00:11:31,424 This is really exciting um genes and biomarkers related to immunology are not commonly found in what I call the box PGX tests such as those uh made by large uh laboratory manufacturing companies um where the panel has a set number of genes and uh you know, 150 00:11:31,434 --> 00:11:36,054 it was developed by a larger laboratory for maybe smaller laboratories use. 151 00:11:36,729 --> 00:11:39,010 So my understanding, 152 00:11:39,020 --> 00:11:53,729 having talked with you extensively theory is that immunology has fewer PGX test available because it's actually more difficult say than oncology to research and develop tests. 153 00:11:53,739 --> 00:11:54,119 So, 154 00:11:54,130 --> 00:12:00,729 could you elaborate for our audience on the difficulties that are associated with immunology, 155 00:12:00,739 --> 00:12:05,830 research and developing tests uh for immunology versus say oncology? 156 00:12:06,330 --> 00:12:06,530 Yeah, 157 00:12:06,539 --> 00:12:07,049 sure. 158 00:12:07,059 --> 00:12:09,969 So in uh in immunology, 159 00:12:09,979 --> 00:12:11,590 as compared to oncology, 160 00:12:11,599 --> 00:12:17,169 there is no such a thing such as a somatic mutation where for example, 161 00:12:17,179 --> 00:12:18,429 you're gonna have a behalf, 162 00:12:18,440 --> 00:12:18,659 you know, 163 00:12:18,669 --> 00:12:20,349 that indicates that the patient, 164 00:12:20,679 --> 00:12:20,919 you know, 165 00:12:20,929 --> 00:12:25,239 is likely to benefit or not from some treatment in immunology. 166 00:12:25,250 --> 00:12:26,750 This is far more complicated, 167 00:12:26,760 --> 00:12:28,830 complicated for the reason, 168 00:12:29,239 --> 00:12:31,020 starting with uh the fact that, 169 00:12:31,030 --> 00:12:31,179 you know, 170 00:12:31,190 --> 00:12:36,219 the response to this uh medication uh are multifactorial. 171 00:12:36,260 --> 00:12:37,820 And the fact that uh you know, 172 00:12:37,830 --> 00:12:39,380 the mutation that uh the, 173 00:12:39,390 --> 00:12:39,619 the, 174 00:12:39,630 --> 00:12:45,190 the single nucleotide polymorphism in the GM line which uh uh you know, 175 00:12:45,200 --> 00:12:52,429 can potentially associate with uh with outcome uh uh uh uh a lo in advance, 176 00:12:52,440 --> 00:12:58,359 meaning that uh they're gonna have a weak association uh with a response to those medications. 177 00:12:58,369 --> 00:13:09,609 So there is a necessity in immunology to combine multiple genetic polymorphism together in order to achieve uh some uh performances characteristics that will make uh you know, 178 00:13:09,619 --> 00:13:09,859 the, 179 00:13:09,869 --> 00:13:10,380 the, 180 00:13:10,390 --> 00:13:10,520 the, 181 00:13:10,530 --> 00:13:13,219 the clinician uh you know, 182 00:13:13,419 --> 00:13:15,619 uh order the test and most importantly, 183 00:13:15,630 --> 00:13:15,840 the, 184 00:13:15,849 --> 00:13:16,179 the, 185 00:13:16,190 --> 00:13:17,739 the payer to pay for the test. 186 00:13:17,750 --> 00:13:20,469 So this field has been uh you know, 187 00:13:20,479 --> 00:13:20,679 is, 188 00:13:20,690 --> 00:13:21,705 is moving for, 189 00:13:21,715 --> 00:13:21,994 you know, 190 00:13:22,005 --> 00:13:24,575 there are some tests that are being developed right now. 191 00:13:24,924 --> 00:13:39,034 But the biggest challenge is to be able to achieve again the the threshold of uh of performance that makes the test is variable enough uh to be uh again ordered by the clinician and the utilize uh to the benefit of the patient. 192 00:13:39,659 --> 00:13:41,200 I couldn't agree with you more. 193 00:13:41,210 --> 00:13:53,489 Um I've worked on the payer side or market access side of pharmacogenomics and even uh with a box test for which there's um a lot of research data available, 194 00:13:53,500 --> 00:13:55,119 even with those, 195 00:13:55,130 --> 00:13:59,760 it's sometimes difficult uh to get payers um to see the value. 196 00:13:59,770 --> 00:14:01,640 So I absolutely agree with you. 197 00:14:01,940 --> 00:14:03,679 Um The fact that you guys are, 198 00:14:03,690 --> 00:14:11,789 are uh investing in producing the data necessary says a lot about your laboratory. 199 00:14:11,979 --> 00:14:12,559 Um you know, 200 00:14:12,570 --> 00:14:15,380 and how committed you are to this testing and, 201 00:14:15,390 --> 00:14:17,320 and how you believe in the testing. 202 00:14:18,039 --> 00:14:23,640 So I just want to make sure that our audience recognizes that, 203 00:14:24,359 --> 00:14:24,619 you know, 204 00:14:24,630 --> 00:14:31,820 Prometheus doesn't simply provide tests to determine if drugs for IBD will be effective and safe. 205 00:14:32,190 --> 00:14:36,900 Um And maybe what the dose of the drug should be for the patient, 206 00:14:36,909 --> 00:14:40,219 but you have that whole suite of tests. 207 00:14:40,229 --> 00:14:47,380 Um the diagnostic test for the differential diagnosis all the way through remission. 208 00:14:48,030 --> 00:14:53,390 So can you elaborate you elaborated on it some in the previous question? 209 00:14:53,400 --> 00:15:01,229 But um can you tell us the difference between how you had to actually develop the test? 210 00:15:01,520 --> 00:15:02,530 Um You didn't, 211 00:15:02,539 --> 00:15:03,059 in other words, 212 00:15:03,070 --> 00:15:10,659 purchase a test from another manufacturer with the biomarkers that you include in your testing. 213 00:15:10,669 --> 00:15:16,830 Can you elaborate on how much more difficult it is to to develop a test from scratch? 214 00:15:18,169 --> 00:15:18,320 Yeah, 215 00:15:18,330 --> 00:15:18,659 sure. 216 00:15:18,669 --> 00:15:18,809 I mean, 217 00:15:18,820 --> 00:15:22,070 this is this is challenging for multiple and first of all, 218 00:15:22,080 --> 00:15:23,130 you need to have the, 219 00:15:23,419 --> 00:15:27,450 you need to have a clinical data set available with specimen available. 220 00:15:27,460 --> 00:15:28,159 Uh you know, 221 00:15:28,169 --> 00:15:28,780 in front, 222 00:15:28,859 --> 00:15:29,770 obviously, 223 00:15:29,859 --> 00:15:30,890 available. 224 00:15:31,200 --> 00:15:35,890 Uh So we are leveraging a pro meters a large bi bank of specimen. 225 00:15:36,299 --> 00:15:37,190 Uh as I said, 226 00:15:37,200 --> 00:15:39,719 Prometheus has been founded 25 years ago. 227 00:15:39,729 --> 00:15:40,599 So over the, 228 00:15:40,760 --> 00:15:41,919 the past two decades, 229 00:15:41,929 --> 00:15:54,849 we have been able to assemble a large uh substrate of data and specimen which we are uh uh using to uh uh establish our proof of concept if you will. 230 00:15:54,859 --> 00:16:07,559 And then when we have uh identify some genetic polymorphism that are uh adequately uh associated with uh uh disease outcome and disease progression as well as uh toxicity. 231 00:16:07,969 --> 00:16:11,469 Then we are entering validation phase where we are uh you know, 232 00:16:11,570 --> 00:16:14,789 using validation cohorts where we are again, 233 00:16:14,969 --> 00:16:22,630 combining multiple modalities together uh patient demographic as well as genetic marker together with theological marker. 234 00:16:22,640 --> 00:16:23,190 Actually, 235 00:16:23,500 --> 00:16:27,419 to come up with some Multivariate models that are uh again, 236 00:16:27,429 --> 00:16:39,250 bringing the performances characteristics of the pharmacogenomic test or its combination with our marker to the level where it's supposed to be in the first place to meet uh uh payer. 237 00:16:39,650 --> 00:16:41,190 And uh obviously, 238 00:16:41,200 --> 00:16:41,760 again, 239 00:16:41,770 --> 00:16:45,320 the patient uh to the benefit of the patient and to, 240 00:16:45,330 --> 00:16:46,619 to improve its outcome, 241 00:16:46,739 --> 00:16:47,429 the outcome. 242 00:16:48,340 --> 00:16:53,380 I think what you're describing really is the future of pharmacogenomics. 243 00:16:53,390 --> 00:16:54,599 Um In other words, 244 00:16:54,609 --> 00:17:03,419 not singing out pharmacogenomics as you know the end all and be all in the treatment paradigm. 245 00:17:03,559 --> 00:17:08,040 But using a PGX test in combination with, 246 00:17:08,050 --> 00:17:09,069 like you mentioned, 247 00:17:09,250 --> 00:17:11,160 other serological tests, 248 00:17:11,170 --> 00:17:12,959 maybe other genetic tests. 249 00:17:13,290 --> 00:17:14,890 Um But you know, 250 00:17:14,900 --> 00:17:25,869 I think what we want our audience to really wrap their heads around is that PGX is just a piece of that larger puzzle um from diagnosis to treatment to, 251 00:17:25,880 --> 00:17:26,910 to remission. 252 00:17:27,239 --> 00:17:29,880 So I think you guys are absolutely, 253 00:17:29,890 --> 00:17:31,579 you're already in the future. 254 00:17:31,589 --> 00:17:32,849 In other words, 255 00:17:32,859 --> 00:17:33,130 you know, 256 00:17:33,140 --> 00:17:39,689 you're already providing all these different uh tests um like you mentioned to, 257 00:17:39,699 --> 00:17:44,310 to facilitate from diagnosis to remission to remission. 258 00:17:44,660 --> 00:17:45,520 That's correct. 259 00:17:45,530 --> 00:17:45,829 Yeah. 260 00:17:46,349 --> 00:17:55,089 So um you've given us so much great information about uh the tests that that you guys offer. 261 00:17:55,329 --> 00:18:02,060 Can you explain to our audience um your newest test? 262 00:18:02,069 --> 00:18:03,859 Uh the responder test. 263 00:18:04,150 --> 00:18:12,979 And um what role it will play in the paradigm from the diagnosis of IBD to remission? 264 00:18:14,050 --> 00:18:14,260 Yeah, 265 00:18:14,270 --> 00:18:14,760 sure. 266 00:18:14,770 --> 00:18:15,569 So we, 267 00:18:15,579 --> 00:18:18,069 we are doing things a little bit different than other. 268 00:18:18,079 --> 00:18:19,489 We do believe that uh you know, 269 00:18:19,500 --> 00:18:21,449 the it has to be simple. 270 00:18:21,459 --> 00:18:24,189 Uh uh We can obviously construct some very, 271 00:18:24,199 --> 00:18:33,530 very complex algorithm and there are some tests that do that with a very sophisticated machine learning based tools that are available using neural networks, 272 00:18:33,540 --> 00:18:33,729 you know, 273 00:18:33,739 --> 00:18:34,790 those sorts of things. 274 00:18:34,800 --> 00:18:39,729 But we have taken on a different approach where with the responder test, 275 00:18:39,739 --> 00:18:40,329 we are basically, 276 00:18:40,339 --> 00:18:45,160 we are taking an approach which is very simple to address the first and foremost. 277 00:18:45,170 --> 00:18:53,020 Most important aspect of responding uh predicting response to uh to medication is the pharmacokinetics. 278 00:18:53,280 --> 00:19:03,250 Uh You cannot be responding to a drug if the drug is not given and you obviously cannot respond to a drug if the drug is not metabolized adequately. 279 00:19:03,359 --> 00:19:06,349 And this is what we are doing with the responder test. 280 00:19:06,579 --> 00:19:09,010 We are addressing some uh uh you know, 281 00:19:09,020 --> 00:19:11,630 fundamental issues with those uh biologist, 282 00:19:11,640 --> 00:19:12,410 for example, 283 00:19:12,660 --> 00:19:15,170 uh the anti tumor necrosis factors. 284 00:19:15,180 --> 00:19:15,650 So, 285 00:19:15,750 --> 00:19:19,199 such as uh Infliximab and Adalimumab, 286 00:19:19,209 --> 00:19:23,050 it is well known uh that uh uh those drugs, 287 00:19:23,060 --> 00:19:25,689 first of all are prone to immunization. 288 00:19:25,989 --> 00:19:36,949 Uh Meaning that uh uh the drug itself uh is recognized by the immune system uh and digested by the antigen presenting cells. 289 00:19:36,959 --> 00:19:42,209 If you will uh where you gonna have uh uh an immune uh uh response, 290 00:19:42,380 --> 00:19:56,979 uh mounted a cancer drug to produce uh immunogen that will severely impact its pharmacokinetics where the labels will be inadequate to produce uh the desired uh anti-inflammatory effects. 291 00:19:56,989 --> 00:19:57,150 So, 292 00:19:57,160 --> 00:19:58,890 we are with the risk conductors, 293 00:19:58,900 --> 00:20:01,040 we are combining two things together. 294 00:20:01,189 --> 00:20:07,959 First of all is the genetic test itself which uh predicts the risk of immun immunization. 295 00:20:07,969 --> 00:20:18,010 The name of the test is on HL A uh DQ A 105 ali uh that uh uh promotes the presentation of the, 296 00:20:18,020 --> 00:20:19,130 of the, 297 00:20:19,140 --> 00:20:19,910 of Infliximab, 298 00:20:20,010 --> 00:20:20,750 for example, 299 00:20:20,760 --> 00:20:32,130 to the T cell repertoire in order to uh promote the Ronon expansion and the formation of the anti antibodies together with uh another dimension which is the clearance, 300 00:20:32,140 --> 00:20:33,670 which is as important. 301 00:20:33,949 --> 00:20:36,209 Uh One of the key issue is the, 302 00:20:36,219 --> 00:20:36,770 the, 303 00:20:36,780 --> 00:20:41,239 the monoclonal antibodies and uh such as Infliximab or Adalimumab. 304 00:20:41,329 --> 00:20:42,280 But in fact, 305 00:20:42,290 --> 00:20:45,890 a neon antibodies that those drugs are uh you know, 306 00:20:45,900 --> 00:20:49,010 cleared and consumed uh from the, 307 00:20:49,020 --> 00:20:50,949 from the central compartment if you will, 308 00:20:50,959 --> 00:20:54,520 since we are doing a little bit of uh uh pharmacokinetics here. 309 00:20:54,530 --> 00:20:56,020 And uh uh you know, 310 00:20:56,030 --> 00:21:06,670 if the patient present who is uh a high degree of inflammatory burden is gonna have uh the patient will have a high clearance and that's gonna worsen uh in the, 311 00:21:06,680 --> 00:21:13,939 in the presence again of the HL AD Q A 105 genetic marker that uh associate with uh immunization. 312 00:21:13,949 --> 00:21:16,859 So I but this is a combination of both, 313 00:21:17,199 --> 00:21:19,359 these are the predictive factors of pharmacokinetic, 314 00:21:20,359 --> 00:21:38,209 which we combine together where the patient presenting with a risk of immunization as well as accelerated clearance due to the fact that the patient has high inflammation or due to the fact that they are so intrinsic pharmacokinetic properties that makes that the patient, 315 00:21:38,219 --> 00:21:38,300 you know, 316 00:21:38,310 --> 00:21:39,479 will clear the drug very, 317 00:21:39,489 --> 00:21:40,260 very fast. 318 00:21:40,560 --> 00:21:41,670 For example, 319 00:21:41,680 --> 00:21:46,819 due to the inefficient uh recirculation of the drug itself with the new, 320 00:21:46,869 --> 00:21:46,930 the, 321 00:21:46,939 --> 00:21:50,599 the the in the reticular on the system. 322 00:21:50,920 --> 00:21:51,619 Together, 323 00:21:51,630 --> 00:22:02,109 those patients presenting with uh uh together these uh poor prognostic factor of pharmacokinetic origin will tend to be severely underdose, 324 00:22:02,380 --> 00:22:06,719 will not be responding to the drug uh adequately as and they, 325 00:22:06,729 --> 00:22:10,719 and they probably should in the first place if you are able to address uh you know, 326 00:22:10,729 --> 00:22:12,270 the the the exposure. 327 00:22:12,439 --> 00:22:14,079 So what we do with this test, 328 00:22:14,089 --> 00:22:21,640 we will be able to inform uh the clinic that the patient is at risk of achieving, 329 00:22:21,650 --> 00:22:30,829 of achieving suboptimal pharmacokinetics and therefore being able to adjust the dose uh uh to start with more adequately. 330 00:22:30,839 --> 00:22:38,650 So that the the the proper uh exposure is achieved uh during induction to again to, 331 00:22:38,660 --> 00:22:39,040 to, 332 00:22:39,050 --> 00:22:39,380 to, 333 00:22:39,390 --> 00:22:40,890 to achieve a better outcome. 334 00:22:41,040 --> 00:22:47,270 And I think the pharmacist will have a very important role to play here in terms of absolutely, 335 00:22:47,280 --> 00:22:51,239 that information is priceless in the management of these medications. 336 00:22:51,250 --> 00:22:54,930 So thanks for elaborating on that. 337 00:22:56,010 --> 00:22:59,040 And if I may add in our previous conversation, 338 00:22:59,050 --> 00:23:00,810 uh before the recording of podcast, 339 00:23:00,819 --> 00:23:08,869 we had discussed um you guys' robust platform for collaborating with payers to obtain market access and reimbursements for the test. 340 00:23:09,109 --> 00:23:14,109 But without stealing the Thunder from uh Prometheus market access and reimbursement team, 341 00:23:14,199 --> 00:23:22,619 can you please uh briefly detail how Prometheus has proactively worked with payers to solve the problem. 342 00:23:22,920 --> 00:23:27,349 Um the population health problem by building the evidence payers want, 343 00:23:27,359 --> 00:23:41,170 want to see um about your test before you go to the market and then build the test and then hope the payers will see the value and the result and then that will improve the market access and reimbursement for your um precision medicine test. 344 00:23:42,160 --> 00:23:42,339 Yeah. 345 00:23:42,349 --> 00:23:43,180 So briefly I can, 346 00:23:43,189 --> 00:23:43,579 I'm, 347 00:23:43,589 --> 00:23:46,619 I'm probably not the right person to answer that question. 348 00:23:46,630 --> 00:23:47,369 We have a very, 349 00:23:47,380 --> 00:23:52,400 very efficient market access group uh uh pro meters that does a splendid job. 350 00:23:52,410 --> 00:23:59,780 But uh uh uh what I can tell you that we have an evidence uh uh development plan in place where we, 351 00:23:59,790 --> 00:24:14,000 we are establishing the clinical utility of our testing solution by demonstrating uh the payer value uh with respect of uh patient management and uh uh and the, 352 00:24:14,010 --> 00:24:16,630 and the impact of our technology on the, 353 00:24:16,640 --> 00:24:18,119 on physician behavior. 354 00:24:18,430 --> 00:24:21,319 Uh We have uh uh already uh you know, 355 00:24:21,329 --> 00:24:25,160 commercialized uh two of those tests for which we have initiated, 356 00:24:25,170 --> 00:24:29,040 initiated the Power studies uh that uh uh you know, 357 00:24:29,050 --> 00:24:32,000 already provide uh you know, 358 00:24:32,104 --> 00:24:34,484 differentiated and the value to, 359 00:24:34,494 --> 00:24:35,915 to the payer where we are, 360 00:24:35,925 --> 00:24:36,025 the, 361 00:24:36,035 --> 00:24:46,005 the clinicians are basically using our technology to make treatment decision uh as well as uh some prospective clinicality study which we are initiating, 362 00:24:46,145 --> 00:24:47,555 initiating to. 363 00:24:47,564 --> 00:24:48,574 Um uh again, 364 00:24:48,584 --> 00:24:49,425 demonstrate the, 365 00:24:49,435 --> 00:24:49,915 the, 366 00:24:49,925 --> 00:24:50,244 the, 367 00:24:50,255 --> 00:24:53,594 the payer value you uh uh we can certainly follow up with, 368 00:24:53,604 --> 00:24:58,755 uh you can certainly follow up with our market access group uh uh as appropriate there. 369 00:24:58,765 --> 00:25:00,765 Uh They can fill you with more information. 370 00:25:01,349 --> 00:25:01,589 No, 371 00:25:01,599 --> 00:25:02,520 that totally makes sense. 372 00:25:02,530 --> 00:25:03,310 That totally makes sense. 373 00:25:03,319 --> 00:25:10,890 But um we're excited that you're also farm d So how did you get to this role of outside the box path? 374 00:25:10,900 --> 00:25:11,550 There? 375 00:25:11,640 --> 00:25:17,530 There may be a pharmacist student or pharmacist wanting to switch or transition into a role such as yours, 376 00:25:17,540 --> 00:25:19,609 which is a Chief Scientific Officer. 377 00:25:19,619 --> 00:25:20,609 I want to learn more. 378 00:25:20,619 --> 00:25:23,920 So how would you um can you talk a little bit about that? 379 00:25:24,560 --> 00:25:24,780 Well, 380 00:25:24,790 --> 00:25:26,270 we are clinical laboratories. 381 00:25:26,280 --> 00:25:29,400 So in order to uh uh to be in my role, 382 00:25:29,410 --> 00:25:34,020 you need to have uh uh you need to have expertise in clinical laboratory science. 383 00:25:34,030 --> 00:25:36,140 So for the students is basically, 384 00:25:36,150 --> 00:25:36,300 you know, 385 00:25:36,310 --> 00:25:40,770 to do the family degree and then complete the family degree with uh a doctorate, 386 00:25:40,780 --> 00:25:40,930 you know, 387 00:25:40,939 --> 00:25:44,260 which is uh focus on clinical laboratory science. 388 00:25:44,270 --> 00:25:46,079 So you can achieve uh uh you know, 389 00:25:46,089 --> 00:25:47,640 the all the elements you need to be, 390 00:25:47,650 --> 00:25:48,219 for example, 391 00:25:48,229 --> 00:25:53,189 board certified uh as uh as as medical laboratory director. 392 00:25:53,199 --> 00:25:55,160 So you can uh uh so, 393 00:25:55,170 --> 00:25:55,589 uh yeah, 394 00:25:55,599 --> 00:25:56,030 this is, 395 00:25:56,040 --> 00:25:56,400 this is, 396 00:25:56,410 --> 00:25:57,209 this is uh you know, 397 00:25:57,219 --> 00:25:59,160 a great opportunity I think for pharmacies, 398 00:25:59,170 --> 00:26:10,800 there is an absolute need to uh have the clinical pharmacist provide uh uh drug information to healthcare professional as well as uh assist patient with the monitoring of their disease, 399 00:26:10,810 --> 00:26:15,229 the effectiveness of the therapy and um and uh you know, 400 00:26:15,239 --> 00:26:16,060 monitoring the, 401 00:26:16,069 --> 00:26:20,969 the side effect and the toxicity from uh from those uh those medication. 402 00:26:24,650 --> 00:26:24,959 Well, 403 00:26:24,969 --> 00:26:32,119 the I know our audience is going to have uh additional questions for you. 404 00:26:32,130 --> 00:26:32,540 I mean, 405 00:26:32,989 --> 00:26:35,609 you've provided them with so much great information, 406 00:26:35,619 --> 00:26:44,959 but it's only the beginning of what they could possibly learn um about um the testing that you do for IBD and, 407 00:26:44,969 --> 00:26:46,729 and even your career path. 408 00:26:47,050 --> 00:26:47,530 So, 409 00:26:47,540 --> 00:26:49,300 if you wouldn't mind telling us, 410 00:26:49,310 --> 00:26:51,359 um because we have to wrap up, 411 00:26:51,369 --> 00:26:52,670 unfortunately, 412 00:26:53,150 --> 00:26:55,810 this episode of the podcast, 413 00:26:55,819 --> 00:27:00,250 uh could you tell us how our audience members might be able to contact you directly. 414 00:27:01,260 --> 00:27:01,449 Yeah, 415 00:27:01,459 --> 00:27:07,079 I can be contacted on my uh on my email at TT W at como slab dot com. 416 00:27:07,949 --> 00:27:08,810 All right. 417 00:27:09,069 --> 00:27:09,300 Well, 418 00:27:09,310 --> 00:27:14,290 thank you again so much uh for joining us on this episode. 419 00:27:14,300 --> 00:27:15,290 We really, 420 00:27:15,300 --> 00:27:29,530 really hope that our listeners um ideas of not only what PGX can be but how PGX can be utilized in a comprehensive testing suite. 421 00:27:29,709 --> 00:27:35,670 We really hope that our a our audience will um listen in and learn this information. 422 00:27:36,280 --> 00:27:37,869 Um And to our audience, 423 00:27:37,880 --> 00:27:39,439 thank you for tuning in. 424 00:27:39,449 --> 00:27:42,619 We really hope that you've learned from this episode. 425 00:27:43,130 --> 00:27:46,339 Uh We do a whole lot of PG Xing here on this podcast. 426 00:27:46,349 --> 00:27:48,380 We talk about PGX Science, 427 00:27:48,390 --> 00:27:52,030 clinical application and the business of PGX. 428 00:27:52,260 --> 00:27:54,880 So we'd love to hear about from you. 429 00:27:55,099 --> 00:27:56,479 I love to hear from you. 430 00:27:56,489 --> 00:27:58,439 Um What can we teach you? 431 00:27:58,449 --> 00:28:00,920 What more can we teach you through our podcast? 432 00:28:00,930 --> 00:28:12,349 So please drop us a message on linkedin and let us know and please share this link to this podcast link episode with everyone so they can tune in and listen to the PGX for promises podcast. 433 00:28:12,520 --> 00:28:15,369 Leave us a review on Apple podcast or Spotify. 434 00:28:15,459 --> 00:28:18,130 And you can also visit us on PGX four, 435 00:28:18,140 --> 00:28:22,989 the number four Rx dot com to listen to all our other episodes. 436 00:28:23,000 --> 00:28:23,079 Well, 437 00:28:23,089 --> 00:28:23,790 thank you. 438 00:28:24,199 --> 00:28:28,750 Thanks for your interest in PGX and for spending some time with us. 439 00:28:28,760 --> 00:28:35,670 Please share this podcast and leave us a review on Apple podcasts or Spotify for all of our episodes. 440 00:28:35,680 --> 00:28:39,390 Please visit PGX four Rx dot com. 441 00:28:39,569 --> 00:28:43,380 That's PGX four Rx dot com.

Do the gods of the Stephen King universe invoke fear or hope?

Systematic Geekology

Play Episode Listen Later Oct 26, 2023 84:01

As part of our year of origins and cosmologies, our hosts, Christian Ashley, Kevin Schaeffer, and TJ Blackwell, discuss the universe of the Stephen King novels - especially looking at King's own life and the Dark Tower novels! What inspires Stephen King and cosmic entities are behind the stories like IT and Gun Slinger?.What is the best novel by Stephen King? What order should I read all Stephen King books? Who is the God in the Stephen King universe? What is the Stephen King universe called? Why is Pennywise scared of Maturin? Is Maturin stronger than Pennywise? Who is the Crimson Queen in the Dark Tower? Is Crimson King same species as Pennywise? How did Stephen King get his inspiration? We discuss it all in this one! Join in the conversation with us on Discord now!.Support our show on Captivate or Patreon, or by purchasing a comfy T-Shirt in our store!.Check out the rest of our year of origins here:https://player.captivate.fm/collection/5f1fafc8-78ed-47a0-8ff7-61267dc68aa5.Check out all of our other episodes covering various book series:https://player.captivate.fm/collection/cd11887b-5998-452c-aa1f-330423162b51.Hear the other episodes Christian is on here:https://player.captivate.fm/collection/ebf4b064-0672-47dd-b5a3-0fff5f11b54c.Check out all of TJ's episodes:https://player.captivate.fm/collection/f4c32709-d8ff-4cef-8dfd-5775275c3c5e.Listen to all of the episodes featuring Kevin:https://player.captivate.fm/collection/84fd7d06-cf1f-48e5-b358-09a01c5a6bc9Mentioned in this episode:Anazao Ministries Podcasts - AMP NetworkCheck out other shows like this on our podcast network! https://anazao-ministries.captivate.fm/Easily subscribe to the show on your platform of choice!https://systematic-geekology.captivate.fm/listen

god fear gods discord stephen king t shirts pennywise dark tower captivate invoke maturin stephen king universe

Los Tenores y el título de Cobreloa en la Primera B

Los Tenores de ADN

Play Episode Listen Later Oct 16, 2023 90:50

Jorge Valdivia, Leo Burgueño, Rodrigo Hernández, Víctor Cruces y Carlos Costas comentaron el triunfo de Cobreloa que significó su regreso a la Primera División tras ocho años, cuestión por la cual charlaron con el delantero de los loínos, David Escalante. También contactaron con nuestros enviados especiales a Maturin, Diego Sáez y Alberto López, para saber de la preparación de La Roja para su duelo ante Venezuela. Además, supieron de las repercusiones de la despedida de Matías Fernández, donde el "Mago" fue una de las figuras.See omnystudio.com/listener for privacy information.

tambi adem venezuela mat primera tulo mago primera divisi cruces la roja alberto l diego s maturin tenores rodrigo hern cobreloa

Melmoth The Wanderer by Charles Robert Maturin ~ Full Audiobook

Classic Audiobook Collection

Play Episode Listen Later Sep 22, 2023 1732:20

Melmoth The Wanderer by Charles Robert Maturin audiobook. One of the first horror novels, it tells the story of Melmoth, who sells his soul so he could have an extended life. Throughout the novel, he wanders around the world in search of someone who would replace him and lift his curse. It is known for its many sub-plots, the true horror it makes one feel, and its criticism of the Catholic church. This is certainly one of the most important books of all times, quoted in countless other works, and praised by authors and critics alike. Learn more about your ad choices. Visit megaphone.fm/adchoices

catholic audiobooks wanderer full audiobook melmoth maturin charles robert

The great reset? How the EU and the UK can rethink their cooperation on foreign policy

Mark Leonard's World in 30 Minutes

Play Episode Listen Later Jul 28, 2023 33:57

War has returned to the European continent, putting many previous divisions into perspective. This has caused European leaders to think afresh about their politics – and raised the question of the United Kingdom's role in European foreign policy. Seven years after the Brexit referendum, the EU and the UK have finally resolved some of their differences through the Windsor Framework. The possibility of a reset between the UK and the EU on foreign policy could be on the horizon. In this year's mini-series, Mark Leonard and Susi Dennison examine what a reimagined EU-UK relationship might look like. In this second episode, Mark and Susi welcome David Lidington, who was the United Kingdom's longest serving minister for European affairs between 2010 and 2016, to discuss what this renewal of relations might look like. How can the Conservative and Labour parties ensure a constructive and forward-looking approach to the UK's relationship with the EU? Can bilateral relationships complement engagement with Brussels in navigating the UK's position in Europe? This podcast was recorded on 23 June 2023. Bookshelf: The Conservative Party After Brexit: Turmoil and Transformation, by Tim Bale What went wrong with Brexit: and what we can do about it, by Peter Foster Aubrey & Maturin series, by Patrick O'Brian

europe uk war european transformation european union united kingdom brexit conservatives labour brussels rethink foreign policy cooperation great reset eu uk mark leonard windsor framework maturin david lidington susi dennison

July 25th 2023 - Hour Two Shelly Maturin interview

witches ballou sea witch maturin

Play Episode Listen Later Jul 25, 2023 44:08

maturin

The Sea-Witch Maturin by Murray Ballou

Awesome Audiobooks

Play Episode Listen Later Nov 24, 2022 261:36

The Sea-Witch Maturin by Murray Ballou

Melmoth, El Errabundo - Charles Robert Maturin

Crónicas Lunares

Play Episode Listen Later Oct 15, 2022 2:37

Octubre 1. La religiosa – Denis Diderot 2. Hiperión – Friedrich Hölderlin 3. El castillo de Rackrent – María Edgeworth 4. Enrique de Ofterdingen – Novalis 5. El sobrino de Rameau – Denis Diderot 6. Las afinidades electivas – Johann Wolfgang von Goethe 7. Michael Kohlhass – Heinrich von Kleist 8. Sentido y sensibilidad – Jane Austen 9. Orgullo y prejuicio – Jane Austen 10. Mansfield Park – Jane Austen 11. Emma – Jane Austen 12. Rob Roy – Sir Walter Scott 13. Frankenstein – Mary Wollstonecraft Shelley 14. Ivanhoe – Sir Walter Scott 15. Melmoth el errabundo – Charles Robert Maturín --- Send in a voice message: https://anchor.fm/irving-sun/message

sentido orgullo johann wolfgang friedrich h melmoth maturin charles robert hiperi

Bennedict Mathurin works out for the Portland Trail Blazers + Mock draft round up

Locked On Blazers – Daily Podcast On The Portland Trail Blazers

Play Episode Listen Later Jun 5, 2022 26:13 Very Popular

Arizona's Bennedict Mathurin did a solo workout for the Portland Trail Blazers on Sunday as the team continues its pre-draft process looking at possible targets with the No. 7 pick in the NBA draft. The solo workout for Mathurin doesn't mean much other than that his agency wanted a solo setting for a workout. But it does mean that the Blazers are interested enough in the 6-6 wing that they obliged that preference and got Mathurin into the practice facility. Portland could be a good fit for Mathurin who is an elite shooter and transition scorer but might have issues scoring in the halfcourt and developing into a consistent high level defender. Mathurin isn't the only prospect the Blazers have scouted closely this week. They've also had eyeballs on Purdue's Jaden Ivey, Duke's AJ Griffin and Notre Dame's Blake Wesley among others. It's smokescreen and due diligence season in the NBA and it's worth remembering that this team of year everything means nothing and nothing means everything. Finally let's look at some mock drafts to close the show were prognosticators have the Blazers eyeing Kentucky's Shaedon Sharpe, Baylor's Jeremey Sochan, Dyson Daniels of the G League Ignite along with Maturin. Music for Locked On Blazers by Drae Slapz. Find more of Drae's work here: https://ffm.bio/thedraeslapz Learn more about your ad choices. Visit podcastchoices.com/adchoices

Bennedict Mathurin works out for the Portland Trail Blazers + Mock draft round up

Locked On Blazers – Daily Podcast On The Portland Trail Blazers

Play Episode Listen Later Jun 5, 2022 26:13

Arizona's Bennedict Mathurin did a solo workout for the Portland Trail Blazers on Sunday as the team continues its pre-draft process looking at possible targets with the No. 7 pick in the NBA draft.The solo workout for Mathurin doesn't mean much other than that his agency wanted a solo setting for a workout. But it does mean that the Blazers are interested enough in the 6-6 wing that they obliged that preference and got Mathurin into the practice facility. Portland could be a good fit for Mathurin who is an elite shooter and transition scorer but might have issues scoring in the halfcourt and developing into a consistent high level defender.Mathurin isn't the only prospect the Blazers have scouted closely this week. They've also had eyeballs on Purdue's Jaden Ivey, Duke's AJ Griffin and Notre Dame's Blake Wesley among others. It's smokescreen and due diligence season in the NBA and it's worth remembering that this team of year everything means nothing and nothing means everything.Finally let's look at some mock drafts to close the show were prognosticators have the Blazers eyeing Kentucky's Shaedon Sharpe, Baylor's Jeremey Sochan, Dyson Daniels of the G League Ignite along with Maturin.Music for Locked On Blazers by Drae Slapz. Find more of Drae's work here: https://ffm.bio/thedraeslapz Learn more about your ad choices. Visit podcastchoices.com/adchoices

Episode 107 - The Thirteen Gun Salute (Part 7)

guns thirteen salute van buren maturin

Play Episode Listen Later Jun 5, 2022 55:48

Stephen heads ashore and compiles the next discreet chapter in Dr. Maturin's guide to better out-of-town business trip accommodations. We debate vital life forces for humans, tapirs, orangutans - anything with a spleen, basically. A real Van Buren makes an appearance, as does the real Geoff Hunt. Ch 6 (2nd part).

GSMC Audiobook Series: Best Mystery and Detective Stories Episode 51: Melmoth the Wanderer, Part 2, by Charles Robert Maturin

GSMC Audiobook Series: Best Mystery and Detective Stories

Play Episode Listen Later May 26, 2022 48:56

In the six volumes of the Library of the World's Best Mystery and Detective Stories, Julian Hawthorne presents us thrilling and mysterious short stories from all corners of the world. The GSMC Audiobook Series presents some of the greatest classic novels, audiobooks, and theatrical presentations from a bygone era. Let Golden State Media Concepts take you on a ride through classic audiobooks read by some of the top audiobook performers of all time. This compiled collection of classic audiobooks contains a wide variety of classic Novels. ***PLEASE NOTE*** GSMC Podcast Network presents these shows and audiobooks as historical content and have brought them to you unedited. Remember that times have changed, and some Audiobooks might not reflect the standards of today's politically correct society. The shows do not necessarily reflect the views, standards, or beliefs of Golden State Media Concepts or the GSMC Podcast Network. Our goal is to entertain, educate, and give you a glimpse into the past.

GSMC Audiobook Series: Best Mystery and Detective Stories Episode 50: Melmoth the Wanderer, Part 1, by Charles Robert Maturin

GSMC Audiobook Series: Best Mystery and Detective Stories

Play Episode Listen Later May 23, 2022 48:58

Les Comiques ont passé la nuit au Canadian Tire !

venezuela hist rico mafia deja inventor italiana incidente ingleses el indio maturin luis zambrano

Play Episode Listen Later Apr 21, 2022 24:00

T'as besoin d'un BBQ ou une tondeuse, Mathilde Roy du Protégez-Vous te dit quoi regarder? Maturin Séguin te présente son village avec la chanson “dans la ferme à Maturin”! Édith Comeau a perdu son metteur en ondes: le petit Mario à la console! La CAQ remonte dans les sondages, encore et encore. Voir https://www.cogecomedia.com/vie-privee/fr/ pour notre politique de vie privée

pass bbq prot la nuit canadian tire comeau la caq maturin

El Corito Histórico #ChayanneSeLlamaElmer 55 - El inventor de Bailadores | El indio Maturin | Sifontes vs Los Ingleses | Mafia italiana en Venezuela

El Corito Histórico

Play Episode Listen Later Apr 3, 2022 38:32

En este #ChayanneSeLlamaElmer los muchachos Javier Lara (en Twitter @vzla_apesta) y Doriann Márquez (en Twitter @Hostioso0294), dan respuesta a las inquietudes históricas dejadas por la audiencia por medio de nuestro SENDO BETA, el “Sistema Elmer Nominal para Discusiones Objetivas BETA”. Esta semana traen contenido sobre la vida de Luis Zambrano, la captura de un capo de la mafia italiana en Venezuela, la existencia o no del Indio Maturín y el Incidente del Cuyuní protagonizado por Domingo Sifontes. Deja tus preguntas para el Chayanne Se Llama Elmer en: https://chayanne.netlify.app/ --- Send in a voice message: https://anchor.fm/coritohistorico/message

Master & Commander: The Far Side of the World

Green Screen

Play Episode Listen Later Mar 18, 2022 70:03

Though still weary from that long train trip to the Urals last episode, Sean and Cody board a British Navy sailing ship headed around Cape Horn as they delve into this swashbuckling 2003 adventure/war film, directed by Peter Weir. In Master & Commander: The Far Side of the World, indefatigable Captain Jack Aubrey (Russell Crowe) can't think about anything except the French man-o'-war he's chasing all over the oceans. But his best friend Maturin (Paul Bettany) is so keen on collecting bugs in the Galapagos Islands that he can barely keep his mind on his job of sawing limbs off teenage crew members injured in battle. A whole lot of cannons go boom when the HMS Surprise finally meets her enemy on, well, the far side of the world. Environmental issues discussed include the effect of the Napoleonic Wars on forests in Europe and Asia, the weird beasts of the Galapagos Islands and how they got that way, “naturalists” in the early 19th century, and more dope on Darwin's famous voyage. How did British short-sightedness in managing their forests come back to bite them during the Napoleonic Wars? How far did they have to go to get timber for their ships? Are Americans still mad at the British for burning down their capital in 1814? What's the history of the Galapagos Islands? Which previous episode was it where we revealed the strange fate of the Beagle, the ship that took Darwin there? Do all historians read Patrick O'Brian novels? How do you pronounce “Maturin”? Who was Alexander von Humboldt and why is there an ocean current named after him? What member of Darwin's 1835 expedition to the Galapagos was still alive at the time this film was made, and how is that even possible? Which actor in this film's cast did one of the podcast hosts have a Twitter exchange with? All these questions and more are lying in wait disguised as a whaler in this adventurous episode of Green Screen. Where You Can Find Master & Commander: The Far Side of the World: https://www.justwatch.com/us/movie/master-and-commander-the-far-side-of-the-world Next Movie Up: Runaway Train (1985) Additional Materials About This Episode

world europe master british americans french environmental humboldt galapagos beagle galapagos islands peter weir green screen napoleonic wars british navy commander the far side cape horn urals maturin hms surprise

Reading Comprehension with Aubrey and Maturin (S2E6 - 3/13/22)

Your Words Against Mine

Play Episode Listen Later Mar 13, 2022 62:12

Our hosts reminisce on their school days while discussing Patrick O'Brian's acclaimed historical fiction series. There's also romantic space dragons, because come on, you know what show this is by now.

reading comprehension maturin

Master and Commander: The Far Side of the World

Hold Up

Play Episode Listen Later Jan 23, 2022 61:50

In 2003 we took to the seas of the early Napoleonic wars with Peter Weir's Naval War Epic, Master and Commander. M&C tells the story of Captain Jack Aubrey and the HMS Surprise, which goes from being the hunter to being hunted, and then to hunting once again the powerful heavy frigate privateer of the French, the Acheron. Russell Crowe stars as Captain Aubrey alongside Paul Bettany as Dr. Maturin, both of whom must manage adversity, cursed seamen, and each other while trying to win despite being outgunned. Master and Commander made a modest return of $211 million from the $150 million budget but garnered 10 Oscar nods and ample critical acclaim. But does it hold up? Listen in as Jon, Colin, and Brent debate naval frottage and cursed seamen as we decide if this one is a Master or a NUB.

master french commander russell crowe paul bettany peter weir napoleonic master and commander commander the far side acheron m c nub maturin hms surprise

Episode88 - Master & Commander (Part 2)

master commander lieutenant maturin

Play Episode Listen Later Jan 23, 2022 72:38

Jack and his new friend eat dinner, and we learn some of the Maturin backstory. The Sophie's new Lieutenant has a mysterious non-connection to Maturin, and while Jack strives to find more men, the crew's problems may be just beginning. Ch 2.

Episode 87 - Master & Commander (Part 1)

Play Episode Listen Later Jan 16, 2022 68:24

Back to where it all started - Royal Navy Lieutenant Jack Aubrey meets a black-coated gentleman named Maturin at a concert, and arguably the world's best book series ensues. Ch 1

master commander maturin

On a appris qu'il y avait un magicien-nudiste au village de Maturin Séguin!

Play Episode Listen Later Jan 12, 2022 23:28

Taxer les non vaccinés, vous en pensez quoi ? Un hôtel de luxe pour chameaux, comme si vous y étiez. Secrets de jobs: Un café qui sert du décaféiné à ses clients désagréable. Voir https://www.cogecomedia.com/vie-privee/fr/ pour notre politique de vie privée

secrets village guin avait appris magicien taxer maturin

El Ayuno aprobado por Dios - Pr. Julio César Barreto

Play Episode Listen Later Jan 5, 2022 47:18

"2 Que me buscan cada día, y quieren saber mis caminos, como gente que hubiese hecho justicia, y que no hubiese dejado la ley de su Dios; me piden justos juicios, y quieren acercarse a Dios. - 3 ¿Por qué, dicen, ayunamos, y no hiciste caso; humillamos nuestras almas, y no te diste por entendido? He aquí que en el día de vuestro ayuno buscáis vuestro propio gusto, y oprimís a todos vuestros trabajadores. - 4 He aquí que para contiendas y debates ayunáis y para herir con el puño inicuamente; no ayunéis como hoy, para que vuestra voz sea oída en lo alto. - 5 ¿Es tal el ayuno que yo escogí, que de día aflija el hombre su alma, que incline su cabeza como junco, y haga cama de cilicio y de ceniza? ¿Llamaréis esto ayuno, y día agradable a Jehová? - 6 ¿No es más bien el ayuno que yo escogí, desatar las ligaduras de impiedad, soltar las cargas de opresión, y dejar ir libres a los quebrantados, y que rompáis todo yugo? - 7 ¿No es que partas tu pan con el hambriento, y a los pobres errantes albergues en casa; que cuando veas al desnudo, lo cubras, y no te escondas de tu hermano?" Isaias 58: 2-7 Mensaje predicado por el pastor Julio César Barreto, expuesto en el Centro Cristiano Internacional El Buen pastor, en la ciudad de Maturin, Venezuela. --- Send in a voice message: https://anchor.fm/julio-barreto-en-podcast/message

venezuela dios jehov ayuno barreto julio c por dios llamar aprobado maturin

Eventos Proféticos Finales (III): El Dictador Mundial

Play Episode Listen Later Dec 20, 2021 61:20

Los desastres se vuelven cada vez más graves, estas señales anuncian el regreso del Señor. Noticias de la ocurrencia de guerras, hambrunas y terremotos y el regreso de Israel activan las alarmas. Ahora se hará evidente la fidelidad de Dios y la inmutabilidad de sus pactos con Israel, y a través de él, Su fidelidad para con la Iglesia. El Pastor de enseñanza Julio César Barreto expuso el tema en el Centro Cristiano Internacional El Buen Pastor, en la ciudad de Maturin, Venezuela. --- Send in a voice message: https://anchor.fm/julio-barreto-en-podcast/message

israel prof venezuela dios ahora mundial noticias ticos iglesia eventos finales barreto julio c el pastor dictador iii el maturin

Jingle del espacio radial Síntesis en Vía de Escape 105.5 FM

The Losers' Club: A Stephen King Podcast

Play Episode Listen Later Nov 27, 2021 0:58

jingle del espacio radial Síntesis en Vía de Escape 105.5 FM. Fue un tiempo maravilloso el que ´pasamos en la señal de la emisora Vía de Escape 105.5 FM, en la ciudad de Maturin, Venezuela. Síntesis es un espacio radial producido por el Pr. Julio César Barreto para Ágape en la radio Podcast & Streaming. Soli Deo Gloria. --- Send in a voice message: https://anchor.fm/julio-barreto-en-podcast/message

pr escape streaming venezuela fue espacio jingle soli deo gloria barreto julio c radial maturin

"TNN Live!" Friday, November 12, 2021

"TNN Live!"

Play Episode Listen Later Nov 12, 2021 120:19

Jennifer Ravain of New Orleans, LA joins us with her attorney, Shelly Maturin. The topic? Jennifer's son Jason was vaccinated at his high school but without parental consent. Shelly represents Jennifer in a lawsuit against Ochsners Medical Center, the entity that vaccinated Jason for COVID-19. Maturin also represents a large group of nurses suing Ochsners for their OSHA COVID-19 vaccine mandate or lose their jobs.

covid-19 new orleans live friday maturin osha covid

Which Stephen King Characters Can Shine?

Play Episode Listen Later Nov 5, 2021 91:24

Senior Hollywood correspondent at Vanity Fair Anthony Breznican joins the Losers at the Mellow Tiger to answer questions from a big ol' Bag of Bones. Questions like "Which Stephen King characters have the shine?"; "Which King story would best lend itself to a VR game?"; and "Which King story should David Fincher adapt?"; and many more. Want to watch the whole conversation on video or even join the Losers next time they record? Become a Maturin patron at www.patreon.com/thebarrens.Follow us on Facebook | Twitter | Instagram | Patreon See acast.com/privacy for privacy and opt-out information.

vr shine bones stephen king losers characters david fincher bag maturin

Maturin Séguin cherche une gardienne pour le village

guin cherche le village gardienne maturin

Play Episode Listen Later Nov 4, 2021 20:10

L'espace Tammy - La sacoche bleue Retour sur le gardiennage chez Val Recul du gouvernement sur la vaccination obligatoire Voir https://www.cogecomedia.com/vie-privee/fr/ pour notre politique de vie privée

Le Roi Stephen - Episode 40 - La Tour Sombre / Le chant de Susannah (Part1)

Le Roi Stephen

Play Episode Listen Later Oct 19, 2021 127:36

Elle m'aime, un peu, beaucoup, passionnément, à la folie, elle m'aime, un peu, beaucoup, pass.... AAAhh non tu fais chier Maturin, tu m'as encore bouffé une Rose ! Comme Susannah me manque..... ça tombe bien Eddie, ce mois-ci on suit les premiers couplets du Chant de Susannah, 6e tome de La Tour Sombre par Stephen King ! Rejoignez-nous sous la bannière du Roi Stephen, on a des tests de paternité fiables !Au programme :Présentation du livre et tour de table des avis (00:01:53)Résumé détaillé (00:14:00)Les questions des fidèles du Roi (01:37:20)Crédits:Artwork : PicturesGénérique: Julien LoisyMontage : Julien LoisyCe podcast est produit par le label Podcut. Retrouvez tous les podcasts du label sur le site http://podcut.studio et pour nous soutenir, faites un tour sur notre Patreon http://www.patreon.com/podcut Envie de discuter des épisodes avec nous ? Rejoignez notre Discord https://discord.com/invite/wjyjZEHnPv Voir Acast.com/privacy pour les informations sur la vie privée et l'opt-out.

pr discord roi stephen king chant envie rejoignez latour le chant podcut maturin le roi stephen la tour sombre roi stephen

Charles Maturin in Marsh's Library

Dublin Gothic

Play Episode Listen Later Oct 13, 2021 52:21

What do dancing curates, and headless mummies, and dog-eared sixteenth-century manuscripts about sexual deviancy have in common? In this episode, Dr Katie Mishler speaks with Dr Tina Morin, senior lecturer in English at University of Limerick, and Dr Jason McElligott, Director of Marsh's Library in Dublin, about Charles Maturin's gothic masterpiece Melmoth the Wanderer (1820) and Marsh's Library's new exhibition, Ragged, livid & on fire: The Wanderings of Melmoth at 200. The panel discuss Maturin's visits to Marsh's Library, imagine what he may have read there and shed light on some bizarre finds within the walls of the library.Dr Katie Mishler is an Irish Research Council Enterprise Partnership Postdoctoral Fellow (2020-2022) in collaboration with the UCD Centre for Cultural Analytics and Museum of Literature Ireland (MoLI). Her current project, Mapping Gothic Dublin: 1820-1900, researches the relationship between Dublin's urban history and the development of Ireland's literary gothic tradition. The research for this podcast is supported by Dr Mishler's postdoctoral project Mapping Gothic Dublin: 1820-1900, funded by an Irish Research Council Enterprise Partnership Fellowship.Producers Ian Dunphy, Benedict Schlepper-Connolly and Graciela Hartung MorcilloSound Ian DunphyMusic CAPE

director university english books ireland writer museum library dublin marsh gothic georgian wanderer limerick ragged wanderings melmoth mishler maturin ucd centre

What Stephen King Stories Should Hit the Stage?

The Losers' Club: A Stephen King Podcast

Play Episode Listen Later Oct 1, 2021 81:12

Chat Sematary host Deanna Chapman joins the Losers at the Mellow Tiger to answer questions from a big ol' Bag of Bones. Questions like "Which Stephen King protagonist do you think has the most wasted potential?"; "What Stephen King film or adaptation would you love to hear John Williams score?"; "Which King work would like to see adapted for the stage?"; and many more. Want to watch the whole conversation on video or even join the Losers next time they record? Become a Maturin patron at www.patreon.com/thebarrens.Follow us on Facebook | Twitter | Instagram | Patreon See acast.com/privacy for privacy and opt-out information.

stories stage bones stephen king losers john williams bag maturin deanna chapman

S02 E05 - Exclusive Interview with Berthe and Maturin

Love via HaShem

Play Episode Listen Later Sep 28, 2021 21:27

Zara and I had the pleasure of sitting down with Berthe and Maturin for an exclusive interview regarding marriage, and marriage with children. They gave very unique insights, and we're quite fortunate to have been able to learn from them. Enjoy! =============================================================== DONATING or SHARING …. are the two biggest things that you can do if you want to support and/or be involved in some way. I want to keep doing this, and with your help, I can keep on keep'n on ;D Here's the donation link: https://anchor.fm/LoveHaShem/support If you share via Instagram, feel free to tag @flowmindset: Thanks for listening! -------------------- (^_^) Stay connected via Instagram: https://www.instagram.com/flowmindset/ YouTube: www.youtube.com/user/TheLinguisticFight Twitter: https://twitter.com/Flow_Mindset Tumblr: linguisticfight.tumblr.com/ --- Support this podcast: https://anchor.fm/lovehashem/support

sharing exclusive donating maturin d here

Dreaming Up Stephen King's It 2 and Pangborn's Last Stand

The Losers' Club: A Stephen King Podcast

Play Episode Listen Later Aug 30, 2021 99:02

Filmmaker and Horror Movie Survival Guide co-host Julia Marchese joins the Losers at the Mellow Tiger to answer questions from a big ol' Bag of Bones. Questions like "What monsters might appear in a sequel novel to It?" "Do we want to see a proper ending for Alan Pangborn?" "Who might we hire Billy Summers to take out in King's Dominion?" What's more, Julia also previews her upcoming Dollar Baby short, I Know What You Need, which just wrapped production in Bangor, Maine. Want to watch the whole conversation on video or even join the Losers next time they record? Become a Maturin patron at www.patreon.com/thebarrensFollow us on Facebook | Twitter | Instagram | Patreon See acast.com/privacy for privacy and opt-out information.

maine bones stephen king losers filmmakers dreaming dominion bag last stand bangor dollar baby billy summers maturin julia marchese pangborn horror movie survival guide i know what you need alan pangborn

Episode 59 - The Far Side Of The World (Part 5)

surprise south america horn norfolk world part far side maturin

Play Episode Listen Later May 30, 2021 67:14

There's time ashore for Maturin and Martin, but the owl-faced night ape takes its toll, and South America offers addictive new possibilities. As the repaired Surprise races to catch the Norfolk, there are complications, a prize in view and the Horn to weather. Ch 5.

Predicación: Hablemos de las Aflicciones - Julio César Barreto

venezuela hablemos barreto julio c predicaci aflicciones maturin

Play Episode Listen Later May 30, 2021 38:00

* Esta predicación contiene la voz de un niñito de 2 años presente entre la audiencia, El tema fue predicado el 30- 05 - 21 en la sede del CCi El Buen Pastor, en la ciudad de Maturin, Venezuela. --- Send in a voice message: https://anchor.fm/julio-barreto-en-podcast/message

Maturin Séguin se prépare à fêter la Fête des Mères avec ses 91 enfants!

Play Episode Listen Later May 4, 2021 38:01

Martin a t'il réussi à battre Guy Jodoin à Dans ta face Cloutier? Une policière filmée dans les locaux du SPVM alors qu'elle était… aux toilettes! On a parlé à quelqu'un qui a passé quelques jours dans le coma. Voir https://www.cogecomedia.com/vie-privee/fr/ pour notre politique de vie privée

dans la f pare enfants guin cloutier spvm maturin guy jodoin

Episode 52 - Treason's Harbour (Part 9)

Play Episode Listen Later Apr 11, 2021 56:02

Wray and Maturin play for high stakes, but Killick saves the chelengk. We return to Kutali, meet old friends, hear Jack fumbling with Greek and Italian, and have a brush with Bogart and Bergman. Ch 9,10

italian greek treason bergman harbour wray bogart killick maturin

Vit syngja tríraddað, tá maturin kemur á borðið

Góðan morgun Føroyar

Play Episode Listen Later Mar 2, 2021 13:19

kemur maturin radda

Porc Académie et la version "Let it truie" des Beatles avec Maturin!

Kingslingers | A Dark Tower Podcast

Play Episode Listen Later Feb 17, 2021 24:56

On débat: au cinéma, es-tu team popcorn ou team "tu fais du bruit avec ton &*@%# de popcorn" ? Maturin Séguin a organisé un Porc Académie dans le village et ça mal viré ! Quel émoji tu ne dois ABSOLUMENT plus utiliser au risque d'avoir l'air vieux et dépassé? Voir https://www.cogecomedia.com/vie-privee/fr/ pour notre politique de vie privée

beatles quel acad absolument porc maturin

53: The Dark Tower (Part 8)

Play Episode Listen Later Jan 14, 2021 147:44

No character deaths this week! Hurray! We're talking all about Chapters 3 and 4 of Part 3 of The Dark Tower Discussion Question: Describe your version of the Maturin Fountain Park. If you don't have one in real life, make one up! Next week, Part 4: The White Lands of Empathica begins as we chat about chapters 1, 2, and 3 Check out the show schedule: https://tinyurl.com/yxa7lojv Support us on Patreon: https://patreon.com/doofmedia Stay updated with Kingslingers: @doofmedia Message us at kingslingerspod@gmail.com Original music created by Matt Freeman: https://soundcloud.com/the-daly-planet/kingslingers-intro-ka-tet Cover artwork created by Cyrix: https://www.reddit.com/user/CyrixDrawsStuff

original chapters dark tower hurray matt freeman maturin

@JRYTHM - #RITMOLUCION EP. 020: WADE ROSS

@JRythm - #RITMOLUCION

Play Episode Listen Later Dec 24, 2020 59:06

Featuring guest DJ set from Wade Ross DJ & producer from Maturin, Venezuela! Who's got a new dubstep festival trap collab “Cosmic Radiation” with Rodrigo Howell out now. See acast.com/privacy for privacy and opt-out information.

dj venezuela maturin cosmic radiation rodrigo howell

Glynn Shelly Maturin

Citizens for a New Louisiana

Play Episode Listen Later Oct 13, 2020 9:20

As part of our mission to inform the public on matters of importance, I'm having conversations with the various people who will appear down-ballot of the presidential election on November […]

glynn maturin

Episode 14 - The Mauritius Command (Final Part); James Albright

command mauritius corbett albright pym maturin

Play Episode Listen Later Jul 19, 2020 68:21

Ian and Mike bring The Mauritius Command to an end: can Jack fare better without Clonfert, Corbett and Pym? Will he have the wind taken out of his sails by Admiral Bertie? He has Stephen on hand, so maybe it will all be well in the end. Our guest naturalist James Albright talks to us about the scientific world of Dr Maturin. Ch 8-10

117. Master and commander, avec Olivier Aranda et Alexandre Jubelin

Paroles d'histoire

Play Episode Listen Later Apr 30, 2020 62:57

Les invités : Olivier Aranda, doctorant en histoire maritime de la Révolution française à Paris-I, et Alexandre Jubelin, animateur du podcast Le Collimateur, chercheur en histoire maritime Les romans et le film : Master and Commander (Peter Weir, 2003), d’après Patrick O’Brian La discussion : Qui est Patrick O’Brian ? (2’15) Le personnage de Maturin, plus développé dans les … Continue reading "117. Master and commander, avec Olivier Aranda et Alexandre Jubelin"

master alexandre aranda avec olivier master and commander le collimateur maturin patrick o'brian

Brasil-América Latina - Sem representação diplomática, brasileiros aguardam resgate na Venezuela

Brasil- América Latina

Play Episode Listen Later Apr 18, 2020 4:19

Os brasileiros que moram, estavam de passagem ou os que estão em prisões na Venezuela, foram pegos de surpresa pelo encerramento das atividades da embaixada e dos consulados do Brasil no país comandado por Nicolás Maduro. Elianah Jorge, correspondente da RFI Brasil em Caracas Nem mesmo a quarentena imposta pela pandemia da Covid-19 fez Brasília adiar os planos divulgados em fevereiro passado. Com a radical decisão, o governo de Jair Bolsonaro congelou as atividades diplomáticas na Venezuela para isolar politicamente o governo bolivariano. A rusga acabou gerando um grande problema para os brasileiros. Entre eles, estão os que anseiam ser resgatados pelo Itamaraty para voltar ao Brasil. É o caso da cirurgiã-dentista Telma Lúcia Mota de Castro. Ela chegou na Venezuela em 27 de fevereiro para participar da formatura do filho. Quando foi ao consulado brasileiro em Caracas pedir um documento, soube que o local seria fechado. Tanto o consulado-geral como os três vice-consulados do Brasil na Venezuela encerraram as atividades em 26 de março deste ano. Os mais de 10 mil brasileiros inscritos no cadastro consular não foram avisados. Com o voo de volta cancelado por causa da pandemia, Telma recorreu ao Itamaraty. A princípio, não obteve resposta. Dias depois, recebeu informações através do número do Gabinete de Gestão de Crise para a América do Sul. “Eu realmente preciso voltar. Onde eu estou não tem água; a luz vai e vem, assim como a internet. Antes a gente tinha racionamento e agora a gente está sem água, realmente. Está muito difícil", afirma ela à RFI. O site do Consulado-Geral do Brasil em Caracas informa que “a comunidade brasileira residente na Venezuela poderá acessar o Portal Consular do Itamaraty para obter informações sobre assistência consular”. Até o fechamento desta matéria, o Itamaraty não havia respondido à RFI onde os brasileiros podem fazer os trâmites consulares após o encerramento das atividades diplomáticas na Venezuela. No entanto, o Ministério de Relações Exteriores (MRE) informou que “temos conhecimento de nove brasileiros não residentes que lá se encontram. Há outros brasileiros, residentes permanentes no país, que procuraram o grupo especial de crise para inquirir sobre a possibilidade de apoio consular. Até o momento, sabemos de 32 nacionais nessa categoria, cujas condições estão sendo estudadas para verificarmos que tipo de auxílio pode ser prestado”. Resgate sob pressão Os brasileiros veem o voo de resgate como a única alternativa para voltar ao Brasil. Foi o que declarou um empresário à RFI, mas sem se identificar: “Se a gente não conseguir embarcar, vamos ficar presos aqui por tempo indeterminado”. O Itamaraty havia organizado apenas o voo para levar de volta os diplomatas e adidos militares que estavam em missão na Venezuela. Mas a pressão gerada pelos incessantes pedidos de resgate levou Brasília a reavaliar a situação. No avião que levou os integrantes do corpo diplomático na última sexta-feira (17), embarcaram pelo menos 14 cidadãos brasileiros. Outro voo organizado pelo Itamaraty para a retirada de brasileiros está sendo esperado para esta segunda-feira (20). É nele que o jogador de futebol Igor Brodani da Luz pretende voltar pra casa. Após mais de 20 dias tentando contato com o Itamaraty, foi avisado sobre o possível voo. O problema é que ele está em Maturin, no nordeste venezuelano e a pelo menos nove horas de estrada até Caracas. Não bastasse a distância, há outro empecilho. “Na região onde eu estou não está tendo gasolina, então estamos tentando achar alguma forma em conjunto”, diz. Apesar da Venezuela possuir uma das maiores reservas de petróleo do mundo, falta combustível em todo o país. As filas diante dos postos de gasolina são quilométricas. Boa parte da frota está parada. Por causa da rígida quarentena, o jogador do Monagas Sport Club precisa pedir um documento às autoridades venezuelanas para poder passar de um estado ao outro até chegar a Caracas, onde irá se encontrar com outros brasileiros que serão resgatados pelo Itamaraty. Ajuda das Forças Armadas da Venezuela Já Maria Luiza Rodrigues Motta, ex-funcionária do vice-consulado brasileiro em Puerto Ayacucho (no sul venezuelano), precisou recorrer à Força Armada Nacional Bolivariana (FANB) para conseguir sair da Venezuela com a filha. Antes, porém, ela entrou em contato com a Divisão de Assistência Consular (DAC) para pedir vaga no avião da Força Aérea Brasileira (FAB), o mesmo no qual voltaram ao Brasil os funcionários do Itamaraty na Venezuela. “Eu tive que sair com o apoio dos militares venezuelanos, não do governo brasileiro porque eu não tive resposta de ninguém. Até cheguei, praticamente, a suplicar que me ajudassem mas, infelizmente, a ordem era retirar apenas os diplomatas. E os cidadãos brasileiras (ficaram) à deriva”. Já o garimpeiro Luis Rodrigues Amorim decidiu tentar a sorte em uma nova jazida, localizada nas imediações da região amazônica de Puerto Ayacucho. Não teve sorte. “A mina era ruim”, segundo ele. Sem dinheiro para voltar para casa em Boa Vista, no norte do Brasil, graças à solidariedade de uma família brasileira ele “não dorme na rua, nem passa fome”. Os recursos nesta cidade são escassos. Falta sinal de telefonia e a conexão de internet é precária.“A gente procurou o consulado, mas o consulado já estava fechado. Tinha encerrado todas as atividades. Então a gente não pôde fazer mais nada", contou. O brasileiro Roberto Coimbra é um publicitário renomado na Venezuela. Foi nomeado cônsul honorário do Brasil no estado Nueva Esparta (onde está a caribenha Ilha de Margarita) pelo presidente Fernando Henrique Cardoso (1995-2003). Os seguintes presidentes brasileiros mantiveram a designação do cargo até que, em 31 de março deste ano, as funções de Roberto foram cessadas com a saída do corpo diplomático. Foi através da cônsul-geral do Brasil em Caracas que ele soube do encerramento das atividades diplomáticas do Brasil na Venezuela. “Oficialmente o Brasil não tem mais nenhum representante consular ou diplomático no território venezuelano. Nós, brasileiros, estamos de certa maneira esperando algum tipo de informação por parte do Brasil sobre como proceder em caso de necessidade. Ou resolver atividades corriqueiras como é tirar ou renovar um passaporte ou oficializar algum tipo de documentação”. A gravidade da falta de representação diplomática representa um risco para os brasileiros, sobretudo aos que estão nas cadeias venezuelanas. Funcionários do Itamaraty faziam as visitas e os auxiliavam nos trâmites com a Justiça venezuelana. “Abandonam cerca de 25 presos que estão em situação catastrófica nas prisões venezuelanas, e de longe não vai ajudar em nada a resolver a situação política que a gente está enfrentando”, reitera. Na opinião de Roberto Coimbra, faltou informação: “Eu estou seguro de que nenhum dos brasileiros que vivem aqui receberam nenhum tipo de informação oficial sobre essa saída”. Questionado pela RFI, o Itamaraty, não respondeu, até o fechamento desta reportagem, onde os brasileiros que moram na Venezuela devem se dirigir para fazer os trâmites consulares. Para Coimbra, “a decisão (de fechar os postos diplomáticos na Venezuela) foi precipitada porque abandona os interesses que o Brasil tem na Venezuela, de longa data. Abandona os brasileiros que estão aqui – os residentes e os em viagem”. Avião de guerra para diplomatas Um problema de logística quase colocou por água abaixo o voo que sairia esta sexta-feira com os diplomatas, adidos militares e suas respectivas famílias. Para fazer o traslado pessoal e de parte da mudança dos funcionários em missão na Venezuela, a Força Aérea Brasileira tinha previsto aterrissar um avião Hércules na Rampa Quatro, setor do principal aeroporto da Venezuela destinado a aeronaves de caráter estatal. No entanto, na hora do recebimento da autorização para pousar, o Ministério da Defesa venezuelano impôs empecilhos alegando que o Hércules é uma aeronave de guerra.

"El Castillo de Leixlip" de Charles Maturin

Cuentos y Relatos

Play Episode Listen Later Apr 3, 2020 45:47

"El Castillo de Leixlip" (Leixlip Castle) es un relato de terror del escritor irlandés Charles Maturin (1782-1824), publicado en 1825. Básicamente, El castillo de Leixlip es un relato clásico de la literatura gótica, con todos los elementos que conforman el género. Musica: Mikko Tarmia "Amnesia The Dark Descent" Jessica Curry "Amnesia A Machine For Pigs" Blog del Podcast: https://lanebulosaeclectica.blogspot.com/

el castillo maturin leixlip

HTU #2: Spooky Clown Running Around

Hot Trash Unlimited

Play Episode Listen Later Sep 17, 2019 27:55

Caleb and Joe reunite after 27 years to destroy the child of podcasting evil It Chapter 2 before it can kill the world turtle Maturin.

running spooky clowns it chapter maturin

Klangwerk Radio Show - EP141 - Nestor Coa

Klangwerk Records Podcast

Play Episode Listen Later Jun 23, 2019 61:00

Hello amigos This week , we have a producer / DJ from Maturin, Venezuela, Peru : Nestor Coa Dj You Can follow the show: Sunday at 21.00 on Radio Vibration Bruxelles 107.2 FM - Mons 91.0 FM http://www.vibration.fm/player/ Monday at 08.00 on HouseOfHouse Radio * http://houseofhouse.be/ * Tuesday at 21.00 on XBeat * http://www.xbeat.org * Wednesday at 22.00 on HouseOfHouse Radio * http://houseofhouse.be/ * BIOGRAPHY He showed interest in music since he was very young, and has not stopped honing his DJ skills through a unique repertoire of musical elements and playlists. His career took off in 2013, thanks to the impulse given him by a couple of friends and his followers, who enjoy the amazing sounds of their mixes. With influences ranging from the pop of the eighties to the House in fusion is a House Music DJ who is not afraid to innovate and try new things. He also considers himself a Young Dj who starts his career at the age of 16, in 2013 he is influenced by Afro-House, Tech, House, Deep, Deep-house and Tech-House, taking his sounds electronic events to his hometown, is among one of the most important and influential DJs in the electronic scene, constantly presenting itself from its beginnings in important events, after party and private parties of the city, (The now), from the beginning of the year 2018 has participated in several important events in the city of Lima-Peru, as they were, Welcome To Winter, Be-Dj and Welcome To Spring, led by the hand by Rave Station, lately this year (2019) I participated in Neon W. ARIVI, being the Warm Up of the event and leaving the Peruvian public fascinated by their Beats, their work continues to expose and expand little by little. LINKS Facebook https://www.facebook.com/NestorCoaDj/ Instagram: https://www.instagram.com/nestorcoadj Soundcloud https://soundcloud.com/nestorcoadj

house deep tech dj venezuela beats djs radio show warm up peruvian tech house nestor afro house lima peru maturin klangwerk radio vibration bruxelles

CronoCine 2x16: Master and Commander (Peter Weir, 2003)

CronoCine

Play Episode Listen Later May 15, 2019 241:19

¡Hola Crononautas! En medio de esta vorágine de Juego de Tronos y los coletazos finales de los Vengadores, cerramos nuestro ciclo sobre pelis de ficción histórica. Hoy traemos un largometraje que sobresale actoralmente gracias a los esfuerzos de Russell Crowe y Paul Bettany, y en una joya de la cinematografía y edición sonora, Master and Commander: Al otro lado del Mundo (Capitán de Mar y Guerra: La costa más lejana del mundo para nuestros amigos americanos) de Peter Weir. Regresan Las Historias del Sr. Lobo, en las que hablaremos sobre las guerras Napoleónicas, el contexto histórico de la cinta. Además, tras el éxito generado por el episodio piloto, hemos decidido convertir en mini sección recurrente los interesantes informes sobre el doblaje al castellano de las películas que tratemos de Manu Gea, que a partir de hora estará a cargo de Doblaje y Acción. En este episodio suena la BSO de CronoCine compuesta por el artista musical El Arias (podéis encontrar su música en Facebook y Soundcloud). Además, suenan las piezas clásicas "Fantasia on a Theme by Thomas Tallis" de Ralph Vaughan Williams y el "Suite No.1 in G major - Prelude" de Johann Sebastian Bach (todas bajo licencias Cretive Commons 4.0).

CronoCine 2x16: Master and Commander (Peter Weir, 2003)

CronoCine

Play Episode Listen Later May 15, 2019 241:19

Killing My Kindle – Episode 2-06: Grice Lightning

Play Episode Listen Later Mar 17, 2019 12:55

Episode 2-06: Grice Lightning Wherein I review: 18 - The Letter of Marque (Aubrey & Maturin #12) by Patrick O'Brian 19 - The Curse of the House of Foskett (The Gower Street Detective #2) by M.R.C. Kasasian 20 - Death Descends on Saturn Villa (The Gower Street Detective #3) by M.R.C. Kasasian 21 - Blade of Tyshalle (The Acts of Caine #2) by Matthew Woodring Stover 22 - The Thirteen-Gun Salute (Aubrey & Maturin #13) by Patrick O'Brian 23 - The Secrets of Gaslight Lane (The Gower Street Detective #4) by M.R.C. Kasasian 24 - Caine Black Knife (The Acts of Caine #3) by Matthew Woodring Stover 25 - Dark Dawn Over Steep House (The Gower Street Detective #5) by M.R.C. Kasasian

house secrets letter killing curse lightning kindle blade caine patrick o grice maturin

Killing My Kindle – Episode 2-05: Suffer Not An Actor To Live

actor killing reverse suffer kindle caine patrick o james rollins maturin

Play Episode Listen Later Feb 24, 2019 9:05

Episode 2-05: Suffer Not An Actor To Live Wherein I review: 14 - Crucible (Sigma Force #14) by James Rollins 15 - The Reverse of the Medal (Aubrey & Maturin #11) by Patrick O'Brian 16 - The Mangle Street Murders (The Gower Street Detective #1) by M.R.C. Kasasian 17 - Heroes Die (The Acts of Caine #1) by Matthew Woodring Stover

Killing My Kindle – Episode 2-4: It’s So Hard to Say Goodbye to Yesterday

blood killing kindle say goodbye george r patrick o maturin

Play Episode Listen Later Feb 11, 2019 9:33

Episode 2-4: It's So Hard to Say Goodbye to Yesterday Wherein I review: 11 - Vultures (Miriam Black #6) by Chuck Wendig 12 - Fire & Blood by George R.R. Martin 13 - The Far Side of the World (Aubrey & Maturin #10) by Patrick O'Brian

Killing My Kindle – Episode 2-03: Misty Water-Colored Memories

Play Episode Listen Later Jan 31, 2019 11:31

Episode 2-03: Misty Water-Colored Memories Wherein I review: 6 - Ex-Purgatory (Ex-Heroes #4) by Peter Clines 7 - No Sunscreen for the Dead (Serge Storms #22) by Tim Dorsey 8 - Treason's Harbour (Aubrey & Maturin #9) by Patrick O'Brian 9 - Ex-Isle (Ex-Heroes #5) by Peter Clines 10 - Cadillac Desert by Marc Reisner

water memories killing kindle treason colored patrick o peter clines maturin tim dorsey cadillac desert marc reisner

Killing My Kindle – Episode 1-50: Duct Taping a Rhino to a Horse Doesn’t Make a Unicorn

Play Episode Listen Later Dec 31, 2018 13:55

Episode 1-50: Duct Taping a Rhino to a Horse Doesn't Make a Unicorn Wherein I review: 187 - The Ionian Command (Aubrey & Maturin #8) by Patrick O'Brian 188 - The Night Ocean by Paul La Farge 189 - The Information by Martin Amis 190 - Ex-Heroes (Ex-Heroes #1) by Peter Clines And thus endeth Season 1 and Cannonball Read 10.

horses killing unicorns kindle rhino taping duct patrick o maturin

Killing My Kindle – Episode 1-46: If Someone Calls You Fat, Eat Them

Play Episode Listen Later Dec 17, 2018 14:09

Episode 1-46: If Someone Calls You Fat, Eat Them Wherein I review: 145. Private Princess (Private #14) by James Patterson 146. Bill the Galactic Hero On The Planet of Bottled Brains (Bill the Galactic Hero #3) by Harry Harrison 147. Elevation by Stephen King 148. The Surgeon's Mate (Aubrey & Maturin #7) by Patrick O'Brian

killing kindle surgeons elevation patrick o maturin galactic hero

Killing My Kindle – Episode 1-45: Backstabber, Hope Grabber, Greedy Little Fit Haver

Play Episode Listen Later Dec 11, 2018 12:28

Episode 1-45: Backstabber, Hope Grabber, Greedy Little Fit Haver Wherein I review: 171. The Devil's Colony (Fatal Folklore Trilogy #3) by Bill Schweigart 172. The Fortune of War (Aubrey & Maturin #6) by Patrick O'Brian 173. Bill, the Galactic Hero and The Planet of the Robot Slaves (Bill the Galactic Hero #2) by Harry Harrison 174. The Witch Elm by Tana French

devil fortune planet killing kindle greedy haver patrick o backstabbers grabber tana french maturin galactic hero

Killing My Kindle – Episode 1-42: The Night is Dark and Full of Terrors

Play Episode Listen Later Nov 9, 2018 13:00

Episode 1-42: The Night is Dark and Full of Terrors Wherein I review: 154. Worst. Person. Ever by Douglas Coupland 155. Season of the Witch: How the Occult Saved Rock and Roll by Peter Bebergal 156. Lincoln in the Bardo by George Saunders 157. The Dark Defiles (A Land Fit for Heroes #3) by Richard K. Morgan 158. Desolation Island (Aubrey & Maturin #5) by Patrick O'Brian TRIPLE CANNONBALL ACHIEVED

night heroes witches dark killing rock and roll kindle bardo terrors patrick o richard k morgan maturin occult saved rock

Killing My Kindle Episode 1-41: Old Timey Fisticuffs

killing kindle map patrick o old timey fisticuffs maturin

Play Episode Listen Later Nov 1, 2018 11:19

Episode 1-41: Old Timey Fisticuffs Wherein I review: 150. The Lost Plot (Invisible Library #4) by Genevieve Cogman 151. A Map of Days (Miss Peregrine #4) by Ransom Riggs 152. Desperate Measures (Stone Barrington #47) by Stuart Woods 153. The Mauritius Command (Aubrey & Maturin #4) by Patrick O'Brian

Killing My Kindle – Episode 1-40: Surprise! I Only Finished One Book This Week

surprise killing finished kindle one book patrick o maturin

Play Episode Listen Later Oct 23, 2018 4:43

Episode 1-40: Surprise! I Only Finished One Book This Week Wherein I review: 149. H.M.S. Surprise (Aubrey & Maturin #3) by Patrick O'Brian

Killing My Kindle – Episode 1-38: I Punched Satan!

Play Episode Listen Later Oct 9, 2018 10:30

Episode 1-38: I Punched Satan! Wherein I review: 144. The Fall of the House of Cabal (Johannes Cabal #5) by Jonathan L. Howard 145. Post Captain (Aubrey & Maturin #2) by Patrick O'Brian

house fall satan killing kindle punched patrick o maturin jonathan l howard

Killing My Kindle – Episode 1-36: Ferris Bueller’s Synthesizer